Traveler's Diarrhea

Infectious Disease MONDO:0001673 Pathograph 29 Show in embeddings browser Infectious diarrhea Travel-related infections

Traveler's diarrhea is an acute infectious gastrointestinal syndrome acquired during or soon after travel, usually through ingestion of food or water contaminated with fecal pathogens. It is etiologically heterogeneous: diarrheagenic Escherichia coli pathotypes, Campylobacter, Shigella, Salmonella, norovirus, and protozoa contribute in proportions that vary by destination and diagnostic method. Most illness is self-limited diarrhea, but fever, bloody diarrhea, dehydration, and persistent postinfectious symptoms can occur. The mechanistic graph below uses enterotoxigenic E. coli (ETEC) as a well-supported exemplar of noninvasive secretory disease rather than as a mechanism shared by every cause of the syndrome.

Ask OpenScientist

Ask a research question about Traveler's Diarrhea. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
15
Pathophys.
10
Phenotypes
3
Gaps
29
Pathograph
10
Medical Actions
3
Differentials
1
Datasets
1
Models
2
Deep Research
🔗

Mappings

MONDO
MONDO:0001673 diarrheal disease
skos:closeMatch MONDO
Closest MONDO parent term available for traveler's diarrhea in the local ontology snapshot.
?

Discussions and Knowledge Gaps

3
How should rapid pathogen identification and destination-specific antimicrobial-resistance surveillance be combined to select self-treatment or clinician-directed therapy for heterogeneous traveler's diarrhea?
KNOWLEDGE GAP OPEN gap_td_pathogen_and_resistance_stratification
Molecular testing increasingly detects viral disease and mixed infections, bacterial rankings differ by method and geography, and susceptibility to fluoroquinolones and macrolides varies markedly across destinations. A universal ETEC-centered or single-antibiotic treatment rule is therefore not supported.
Show evidence (2 references)
PMID:41591385 SUPPORT Human Clinical
"In this cross-sectional study of travelers' diarrhea antimicrobial resistance patterns, there was marked variability of nonsusceptibility to 2 major classes of antibiotics commonly used for treating travelers' diarrhea among global regions."
Directly establishes regional variation in susceptibility to the major empiric antibiotic classes.
PMID:40699254 SUPPORT Other
"Viral travellers' diarrhoea is more frequently recognised due to the improved sensitivity of molecular diagnostics."
Supports the diagnostic-method dependence of observed etiology.
Which pathogen-specific, microbiome, epithelial, and host-response mechanisms determine who develops persistent postinfectious irritable bowel syndrome after traveler's diarrhea?
KNOWLEDGE GAP OPEN gap_td_postinfectious_ibs_mechanism
Attached to
phenotypes#Post-infectious irritable bowel syndrome
PI-IBS is a clinically documented sequela, but the available cohort evidence identifies associations rather than a causal mechanism that can honestly be joined to the acute ETEC secretory graph.
Show evidence (2 references)
PMID:36881659 SUPPORT Human Clinical
"Parasitic infections, mainly giardiasis, seem to be associated with PI-IBS."
Identifies a pathogen-class association without resolving the downstream mechanism.
PMID:40699254 SUPPORT Other
"Better pathophysiological understanding and new intervention strategies are required to help alleviate the suffering of post-travellers' diarrhoea IBS."
Explicitly identifies the unresolved post-travel PI-IBS pathophysiology as a research priority.
Can enteral magnesium activation of epithelial CaSR safely reduce cyclic-nucleotide-mediated secretion in human ETEC traveler's diarrhea?
EMERGING HYPOTHESIS OPEN hypothesis_td_enteral_magnesium_casr_translation
Attached to
pathophysiology#CFTR-mediated epithelial chloride secretion pathophysiology#Net intestinal electrolyte and water secretion
Magnesium suppressed heat-stable-enterotoxin-induced chloride secretion in human T84 cells and reduced toxin-driven fluid accumulation in mouse models, but this remains preclinical evidence from epithelial and animal systems. It is not an established treatment for traveler's diarrhea, and human dose, safety, efficacy, and the risk of osmotic diarrhea remain unresolved.
Show evidence (2 references)
DOI:10.1172/jci171249 SUPPORT In Vitro
"Mg2+ (10 mM) also suppressed Cl- secretion induced by cholera toxin, heat-stable E. coli enterotoxin, and vasoactive intestinal peptide by 50%."
Provides direct preclinical evidence that magnesium suppresses heat-stable-enterotoxin-induced secretion in an epithelial model.
DOI:10.1172/jci171249 SUPPORT Model Organism
"In mouse intestinal closed loops, luminal Mg2+ treatment (20 mM) inhibited cholera toxin–induced fluid accumulation by 40%."
Provides complementary in vivo mouse evidence for reduced toxin-driven intestinal fluid accumulation.
⚙

Pathophysiology

15
ETEC colonization-factor adhesion to small-intestinal enterocytes
In the ETEC subset of traveler's diarrhea, bacterial colonization factors bind receptors on small-intestinal enterocytes and establish close epithelial colonization, positioning toxin-producing organisms at the mucosal surface.
enterocyte of epithelium of small intestine CL:1000334 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves enterocyte of epithelium of small intestine (CL:1000334). CL:1000334 is a cell type from the Cell Ontology.
adhesion of symbiont to host cell GO:0044650 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves adhesion of symbiont to host cell (GO:0044650). GO:0044650 is a biological process from the Gene Ontology.
small intestine UBERON:0002108 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in small intestine (UBERON:0002108). UBERON:0002108 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Heat-stable enterotoxin activation of epithelial GUCY2C Colonization places ST-producing ETEC at the epithelial surface; toxin production and release are omitted intermediates.
Heat-labile enterotoxin activation of epithelial G protein-adenylyl cyclase Colonization places LT-producing ETEC at the epithelial surface; toxin production, release, and uptake are omitted intermediates.
Show evidence (1 reference)
PMID:35358002 SUPPORT Other
"ETEC is characterized by the ability to produce major virulence factors including colonization factors (CFs) and enterotoxins, that bind to specific receptors on epithelial cells and induce diarrhea."
Supports receptor-binding colonization factors as part of ETEC epithelial pathogenesis.
Heat-stable enterotoxin activation of epithelial GUCY2C
ETEC heat-stable enterotoxin binds guanylyl cyclase C (GUCY2C) on intestinal epithelium and increases the receptor's guanylate-cyclase activity.
enterocyte of epithelium of small intestine CL:1000334 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves enterocyte of epithelium of small intestine (CL:1000334). CL:1000334 is a cell type from the Cell Ontology.
GUCY2C hgnc:4688 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves GUCY2C (hgnc:4688). hgnc:4688 is a gene from the HUGO Gene Nomenclature Committee.
guanylate cyclase activity GO:0004383 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves increased guanylate cyclase activity (GO:0004383). GO:0004383 is a molecular function from the Gene Ontology. ↑ INCREASED
small intestine UBERON:0002108 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in small intestine (UBERON:0002108). UBERON:0002108 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
GUCY2C-dependent cGMP production Ligand-activated GUCY2C catalyzes formation of cGMP.
Show evidence (1 reference)
PMID:11952098 SUPPORT Other
"Guanylyl cyclase C (GC-C) was found to function as the principal receptor for heat-stable enterotoxins (STa), major causative factors in E. coli-induced secretory diarrhea."
Identifies GUCY2C as the principal epithelial receptor for E. coli heat-stable enterotoxin.
Heat-labile enterotoxin activation of epithelial G protein-adenylyl cyclase
ETEC heat-labile enterotoxin binds an intestinal epithelial receptor and delivers an enzymatic subunit that modifies the G protein coupled to adenylyl cyclase, increasing cyclase activity.
enterocyte of epithelium of small intestine CL:1000334 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves enterocyte of epithelium of small intestine (CL:1000334). CL:1000334 is a cell type from the Cell Ontology.
adenylate cyclase activity GO:0004016 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves increased adenylate cyclase activity (GO:0004016). GO:0004016 is a molecular function from the Gene Ontology. ↑ INCREASED
small intestine UBERON:0002108 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in small intestine (UBERON:0002108). UBERON:0002108 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Adenylyl-cyclase-dependent cAMP production Toxin-mediated G-protein modification stimulates adenylyl cyclase and cAMP production.
Show evidence (1 reference)
PMID:1480112 SUPPORT Other
"Both toxins bind receptors in intestinal epithelial cells and insert an enzymatic subunit that modifies a G protein associated with the adenylate cyclase complex."
Directly supports the receptor-to-G-protein/adenylyl-cyclase step for E. coli heat-labile toxin.
GUCY2C-dependent cGMP production
Activated epithelial GUCY2C increases intracellular cGMP, initiating the secretory signaling branch.
enterocyte of epithelium of small intestine CL:1000334 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves enterocyte of epithelium of small intestine (CL:1000334). CL:1000334 is a cell type from the Cell Ontology.
GUCY2C hgnc:4688 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves GUCY2C (hgnc:4688). hgnc:4688 is a gene from the HUGO Gene Nomenclature Committee.
cGMP biosynthetic process GO:0006182 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cGMP biosynthetic process (GO:0006182). GO:0006182 is a biological process from the Gene Ontology. ↑ INCREASED
small intestine UBERON:0002108 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in small intestine (UBERON:0002108). UBERON:0002108 is an anatomical location from the Uberon multi-species anatomy ontology.
Experimental models
Human and mouse intestinal enteroid ST-secretion model ORGANOID The enteroids retain the canonical GUCY2C-to-cGMP-to-PKG signaling axis needed for heat-stable-enterotoxin secretion.
Downstream
CFTR-mediated epithelial chloride secretion cGMP activates PKG, which promotes CFTR opening.
Inhibition of NHE3-mediated epithelial sodium absorption cGMP/PKG signaling inhibits the apical sodium-hydrogen exchanger.
Show evidence (1 reference)
PMID:27481254 SUPPORT In Vitro
"Enteroid secretion depended on canonical molecular signaling events responsible for ETEC-induced diarrhea, including cyclic GMP (cGMP) produced by GUCY2C, activation of cGMP-dependent protein kinase (PKG), and opening of the cystic fibrosis transmembrane conductance regulator (CFTR)."
Human and mouse intestinal enteroids connect GUCY2C-derived cGMP to PKG and CFTR opening.
Adenylyl-cyclase-dependent cAMP production
Toxin-activated epithelial adenylyl cyclase increases intracellular cAMP and drives the secretory signaling branch.
enterocyte of epithelium of small intestine CL:1000334 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves enterocyte of epithelium of small intestine (CL:1000334). CL:1000334 is a cell type from the Cell Ontology.
cAMP biosynthetic process GO:0006171 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cAMP biosynthetic process (GO:0006171). GO:0006171 is a biological process from the Gene Ontology. ↑ INCREASED
small intestine UBERON:0002108 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in small intestine (UBERON:0002108). UBERON:0002108 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
CFTR-mediated epithelial chloride secretion Increased cAMP activates PKA, which promotes CFTR-dependent chloride secretion.
Show evidence (1 reference)
PMID:1480112 SUPPORT Other
"The consequent stimulated production of cyclic AMP, or other factors such as increased synthesis of prostaglandins by intoxicated cells, initiates a metabolic cascade that results in the excessive secretion of fluid and electrolytes characteristic of the disease."
Connects heat-labile-toxin action to increased cAMP and the downstream secretory cascade.
CFTR-mediated epithelial chloride secretion
cGMP/PKG and cAMP/PKA signaling increase opening of apical CFTR channels and chloride secretion into the intestinal lumen.
enterocyte of epithelium of small intestine CL:1000334 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves enterocyte of epithelium of small intestine (CL:1000334). CL:1000334 is a cell type from the Cell Ontology.
CFTR hgnc:1884 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves CFTR (hgnc:1884). hgnc:1884 is a gene from the HUGO Gene Nomenclature Committee.
chloride transmembrane transport GO:1902476 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased chloride transmembrane transport (GO:1902476). GO:1902476 is a biological process from the Gene Ontology. ↑ INCREASED
chloride channel activity GO:0005254 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves increased chloride channel activity (GO:0005254). GO:0005254 is a molecular function from the Gene Ontology. ↑ INCREASED
small intestine UBERON:0002108 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in small intestine (UBERON:0002108). UBERON:0002108 is an anatomical location from the Uberon multi-species anatomy ontology.
Experimental models
Human and mouse intestinal enteroid ST-secretion model ORGANOID CFTR opening is required for the enteroid secretory response, and pharmacologic CFTR inhibition rescues the fluid-accumulation readout.
Downstream
Net intestinal electrolyte and water secretion Luminal chloride secretion draws counterions and water into the intestinal lumen.
Show evidence (1 reference)
PMID:27481254 SUPPORT In Vitro
"Importantly, pharmacological inhibition of CFTR abrogated enteroid fluid secretion, providing proof of concept for the utility of this model to screen antidiarrheal agents."
Shows that CFTR activity is required for enterotoxin-induced fluid secretion in intestinal enteroids.
Inhibition of NHE3-mediated epithelial sodium absorption
GUCY2C/cGMP signaling inhibits the apical sodium-hydrogen exchanger, decreasing epithelial sodium absorption.
enterocyte of epithelium of small intestine CL:1000334 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves enterocyte of epithelium of small intestine (CL:1000334). CL:1000334 is a cell type from the Cell Ontology.
SLC9A3 hgnc:11073 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves SLC9A3 (hgnc:11073). hgnc:11073 is a gene from the HUGO Gene Nomenclature Committee.
sodium ion transmembrane transport GO:0035725 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased sodium ion transmembrane transport (GO:0035725). GO:0035725 is a biological process from the Gene Ontology. ↓ DECREASED
sodium:proton antiporter activity GO:0015385 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased sodium:proton antiporter activity (GO:0015385). GO:0015385 is a molecular function from the Gene Ontology. ↓ DECREASED
small intestine UBERON:0002108 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in small intestine (UBERON:0002108). UBERON:0002108 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Net intestinal electrolyte and water secretion Reduced sodium absorption reinforces net luminal electrolyte and water accumulation.
Show evidence (1 reference)
PMID:11952098 SUPPORT Other
"In the intestine, activation of GC-C results in a dual action: stimulation of Cl and HCO3 secretion, through the opening of apical CFTR Cl channels; and inhibition of Na absorption, through blockade of an apical Na/H exchanger."
Directly supports reduced sodium absorption through blockade of an apical sodium-hydrogen exchanger.
Net intestinal electrolyte and water secretion
Increased anion secretion together with reduced sodium absorption produces net electrolyte and water accumulation in the intestinal lumen.
small intestine UBERON:0002108 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in small intestine (UBERON:0002108). UBERON:0002108 is an anatomical location from the Uberon multi-species anatomy ontology.
Experimental models
Human and mouse intestinal enteroid ST-secretion model ORGANOID Heat-stable enterotoxin produces quantifiable fluid accumulation within enteroid lumens, recapitulating the net secretory output of ETEC disease.
Downstream
Acute watery diarrhea Excess luminal fluid is passed as loose, watery stool.
Dehydration Sustained gastrointestinal water and electrolyte loss that exceeds replacement can deplete systemic volume and cause dehydration.
Show evidence (1 reference)
PMID:1480112 SUPPORT Other
"The consequent stimulated production of cyclic AMP, or other factors such as increased synthesis of prostaglandins by intoxicated cells, initiates a metabolic cascade that results in the excessive secretion of fluid and electrolytes characteristic of the disease."
Supports the final secretory output of the ETEC heat-labile-toxin branch.
Shigella invasion of the colonic epithelium
In the Shigella subset of traveler's diarrhea, organisms invade the colonic epithelium and deliver type III secretion-system effectors into host cells. This branch is pathogen-conditioned and is separate from the ETEC enterotoxin mechanism.
colonocyte CL:1000347 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves colonocyte (CL:1000347). CL:1000347 is a cell type from the Cell Ontology.
colonic epithelium UBERON:0000397 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in colonic epithelium (UBERON:0000397). UBERON:0000397 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Cytokine-mediated colonic inflammation Invasion and injected bacterial effectors activate epithelial and innate immune signaling that elicits intense colonic inflammation.
Show evidence (1 reference)
PMID:23318141 SUPPORT Other
"Shigella, the causative agent of bacillary dysentery, invades the colonic epithelium where it elicits an intense inflammation leading to tissular destruction."
Supports Shigella invasion as the initiating event upstream of intense inflammation and tissue destruction.
Cytokine-mediated colonic inflammation
In Shigella-associated disease, epithelial invasion triggers a cytokine-mediated inflammatory response in the colon. This inflammation is separated from the downstream epithelial necrosis and ulceration that it promotes.
inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
colonic mucosa UBERON:0000317 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in colonic mucosa (UBERON:0000317). UBERON:0000317 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Colonic epithelial necrosis and mucosal ulceration The intense inflammatory response causes epithelial necrosis, colitis, and mucosal ulceration through immune effector injury.
Fever The inflammatory response can produce febrile diarrhea through systemic cytokine signaling.
Show evidence (1 reference)
PMID:21413292 SUPPORT Other
"The pathogenic mechanism of shigellosis is complex, involving a possible enterotoxic and/or cytotoxic diarrheal prodrome, cytokine-mediated inflammation of the colon, and necrosis of the colonic epithelium."
Supports cytokine-mediated colonic inflammation upstream of epithelial necrosis.
Colonic epithelial necrosis and mucosal ulceration
In severe Shigella-associated colitis, inflammatory and cytotoxic injury produces necrosis of the colonic epithelium and ulceration of the mucosa.
colonocyte CL:1000347 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves colonocyte (CL:1000347). CL:1000347 is a cell type from the Cell Ontology.
colonic mucosa UBERON:0000317 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in colonic mucosa (UBERON:0000317). UBERON:0000317 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Bloody diarrhea Ulcerated colonic mucosa permits blood and mucus to enter dysenteric stool.
Show evidence (1 reference)
PMID:21413292 SUPPORT Other
"The resulting colitis and ulceration of the mucosa result in bloody, mucoid stools, and/or febrile diarrhea."
Directly connects colitis and mucosal ulceration to bloody stool.
Protozoal infection associated with persistent traveler's diarrhea
Intestinal protozoa are a pathogen-conditioned cause of protracted diarrhea during or after travel. This syndrome-level node does not assign one parasite-specific epithelial mechanism to Giardia, Cryptosporidium, Cyclospora, and other protozoa.
Downstream
Persistent diarrhea Parasite-specific epithelial and host-response mechanisms are omitted because they differ across protozoal causes.
Show evidence (1 reference)
PMID:11389503 SUPPORT Other
"Intestinal protozoa account for a minority of cases of acute traveler's diarrhea, but they are common pathogens in travelers who experience protracted diarrhea during or after travel."
Directly establishes protozoal infection as a cause of protracted travel-associated diarrhea.
DNA Gyrase and Topoisomerase IV (Fluoroquinolone Target)
Susceptible bacterial causes of traveler's diarrhea depend on DNA gyrase and topoisomerase IV; fluoroquinolones trap their DNA-enzyme complexes and block bacterial DNA replication. This is a therapeutic vulnerability rather than a syndrome-wide causal mechanism.
DNA Topological Change GO:0006265 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves DNA Topological Change (GO:0006265). GO:0006265 is a biological process from the Gene Ontology.
Show evidence (1 reference)
PMID:27449972 SUPPORT Other
"Quinolones dually target DNA gyrase and topoisomerase IV binding to specific domains and conformations so as to block DNA strand passage catalysis and stabilize DNA-enzyme complexes that block the DNA replication apparatus and generate double breaks in DNA that underlie their bactericidal activity."
Defines the bacterial topoisomerase target and bactericidal mechanism of fluoroquinolones.
Bacterial mRNA Translation by the Ribosome
Bacterial ribosomal translation is the conserved molecular target of macrolides such as azithromycin. This node represents an antibiotic vulnerability of susceptible bacterial etiologies, not a mechanism of viral or protozoal disease.
translation GO:0006412 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves translation (GO:0006412). GO:0006412 is a biological process from the Gene Ontology.
Show evidence (1 reference)
PMID:24336183 SUPPORT Other
"The ribosome is one of the main antibiotic targets in the bacterial cell."
Establishes the bacterial ribosome as a central antibiotic target.
Bacterial RNA Polymerase (Rifamycin Target)
Bacterial DNA-dependent RNA polymerase is the molecular target of rifamycins, including the nonabsorbed derivative rifaximin used for selected noninvasive E. coli disease.
DNA-templated transcription GO:0006351 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves DNA-templated transcription (GO:0006351). GO:0006351 is a biological process from the Gene Ontology.
Show evidence (1 reference)
PMID:32342856 SUPPORT Other
"The most clinically important and extensively studied class of antibiotics known to inhibit bacterial RNAP are the rifamycins."
Directly establishes bacterial RNA polymerase as the rifamycin target.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Traveler's Diarrhea Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Digestive 5
Acute watery diarrhea HP:0002014 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Diarrhea (HP:0002014). HP:0002014 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39530798 SUPPORT Human Clinical
"Symptoms can range from mild cramps and loose stool to bloody diarrhea, fever, abdominal pain, and vomiting."
Supports loose stool as a core manifestation across the clinical spectrum.
Nausea 38% (61/160) in a prospective traveler cohort HP:0002018 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Nausea (HP:0002018). HP:0002018 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22099542 SUPPORT Human Clinical
"Nausea2 61 (38) 25 (23) 36 (68)"
The prospective cohort's Table 4 reports nausea in 61 of 160 affected travelers (38%).
Bowel urgency 71% (114/160) in a prospective traveler cohort HP:0012701 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bowel urgency (HP:0012701). HP:0012701 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22099542 SUPPORT Human Clinical
"Fecal urgency 1 114 (71) 69 (65) 45 (85)"
Directly reports fecal urgency in 71% of affected travelers.
Vomiting HP:0002013 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Vomiting (HP:0002013). HP:0002013 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39530798 SUPPORT Human Clinical
"Symptoms can range from mild cramps and loose stool to bloody diarrhea, fever, abdominal pain, and vomiting."
Directly identifies vomiting in the observed clinical spectrum.
Bloody diarrhea HP:0025085 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bloody diarrhea (HP:0025085). HP:0025085 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39530798 SUPPORT Human Clinical
"Symptoms can range from mild cramps and loose stool to bloody diarrhea, fever, abdominal pain, and vomiting."
Directly identifies bloody diarrhea within the observed clinical spectrum.
Metabolism 2
Fever HP:0001945 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fever (HP:0001945). HP:0001945 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39530798 SUPPORT Human Clinical
"Symptoms can range from mild cramps and loose stool to bloody diarrhea, fever, abdominal pain, and vomiting."
Directly identifies fever within the observed clinical spectrum.
Dehydration HP:0001944 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dehydration (HP:0001944). HP:0001944 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31084597 SUPPORT Other
"Dehydration is the most common complication."
Directly supports dehydration as the principal complication.
Constitutional 1
Abdominal cramps or pain Abdominal pain HP:0002027 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abdominal pain (HP:0002027). HP:0002027 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39530798 SUPPORT Human Clinical
"Symptoms can range from mild cramps and loose stool to bloody diarrhea, fever, abdominal pain, and vomiting."
Directly identifies cramps and abdominal pain in travelers with diarrhea.
Other 2
Persistent diarrhea Protracted diarrhea HP:0004385 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Protracted diarrhea (HP:0004385). HP:0004385 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:11389503 SUPPORT Other
"Intestinal protozoa account for a minority of cases of acute traveler's diarrhea, but they are common pathogens in travelers who experience protracted diarrhea during or after travel."
Supports protracted diarrhea as a clinically important protozoal presentation during or after travel.
Post-infectious irritable bowel syndrome MONDO:0005052 Mondo Disease Ontology (MONDO) Relation: this clinical feature is this phenotype This clinical feature is irritable bowel syndrome (MONDO:0005052). MONDO:0005052 is a phenotype from the Mondo Disease Ontology.
Show evidence (1 reference)
PMID:36881659 SUPPORT Human Clinical
"We identified 669 travellers with a diagnosis of TD. Sixty-eight (10.2%) of these travellers, mean age 33 years and 36 (52.9%) women, developed PI-IBS."
Quantifies PI-IBS in a retrospective referral-center cohort after traveler's diarrhea.
💊

Medical Actions

10
Supportive management without antibiotics for mild illness
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Mild traveler's diarrhea is managed with hydration and symptom-directed care; routine antibiotics are not recommended when illness is tolerable and does not interfere with planned activities.
Show evidence (2 references)
PMID:31084597 SUPPORT Other
"For mild travelers' diarrhea, the use of antibiotic is not recommended."
Directly supports antibiotic stewardship for mild illness.
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"Tolerable, not distressing, does not interfere with planned activities"
Defines mild traveler's diarrhea by functional impact.
Oral rehydration therapy
Action: fluid replacement therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is fluid replacement therapy, annotated with Hydration Therapy (NCIT:C66896). NCIT:C66896 is a clinical intervention from the NCI Thesaurus. Ontology label: Hydration Therapy NCIT:C66896
Oral replacement of water and electrolytes is first-line supportive treatment; intravenous rehydration is reserved for severe dehydration or sepsis.
Mechanism Target:
BYPASSES Net intestinal electrolyte and water secretion — Rehydration replaces the water and electrolytes lost through ongoing intestinal secretion without requiring toxin-pathway inhibition.
Show evidence (1 reference)
PMID:35839362 SUPPORT Other
"In all cases, management begins with replacing water, electrolytes, and nutrients. Oral rehydration is preferred; however, signs of severe dehydration or sepsis warrant intravenous rehydration."
Supports replacement therapy as a compensatory intervention for diarrheal fluid and electrolyte loss.
Show evidence (1 reference)
PMID:35839362 SUPPORT Other
"In all cases, management begins with replacing water, electrolytes, and nutrients. Oral rehydration is preferred; however, signs of severe dehydration or sepsis warrant intravenous rehydration."
Supports oral rehydration as preferred initial management and identifies escalation conditions.
Loperamide for mild illness
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: loperamide CHEBI:6532 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses loperamide (CHEBI:6532). CHEBI:6532 is a therapeutic agent from Chemical Entities of Biological Interest.
Loperamide can provide symptom relief in mild traveler's diarrhea, but it should not be used as monotherapy when bloody diarrhea or fever suggests invasive or inflammatory disease.
Show evidence (2 references)
PMID:28521004 SUPPORT Other
"Strong evidence supports the effectiveness of antimicrobial therapy in most cases of moderate to severe travelers' diarrhea, while either increasing intake of fluids only or loperamide or bismuth subsalicylate may suffice for most cases of mild diarrhea."
Graded guideline support for loperamide as an option in mild disease.
url:https://www.ncbi.nlm.nih.gov/books/NBK620898/ SUPPORT Other
"Antimotility agents alone are not recommended for patients with bloody diarrhea or those who have diarrhea and fever."
Establishes the red-flag limitation against loperamide monotherapy in dysenteric or febrile illness.
Bismuth subsalicylate for mild illness or short-term prophylaxis
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: bismuth subsalicylate CHEBI:261649 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses bismuth subsalicylate (CHEBI:261649). CHEBI:261649 is a therapeutic agent from Chemical Entities of Biological Interest.
Bismuth subsalicylate is a non-antibiotic option for symptom management in mild illness and can reduce short-term traveler's-diarrhea incidence by about 50%. Prophylactic use is limited by frequent dosing, lack of safety data beyond three weeks, and contraindications including aspirin allergy, gout, renal insufficiency, and interacting medicines.
Show evidence (4 references)
PMID:28521004 SUPPORT Other
"Strong evidence supports the effectiveness of antimicrobial therapy in most cases of moderate to severe travelers' diarrhea, while either increasing intake of fluids only or loperamide or bismuth subsalicylate may suffice for most cases of mild diarrhea."
Graded guideline support for bismuth subsalicylate as an option in mild disease.
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"The primary agent studied for prevention of TD, other than antibiotics, is bismuth subsalicylate (BSS). Studies from Mexico have shown that this agent reduces the incidence of TD by approximately 50%."
Establishes BSS as the principal studied non-antibiotic prophylactic and quantifies the reported incidence reduction.
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"Travelers with aspirin allergy, gout, or renal insufficiency and those taking anticoagulants, methotrexate, or probenecid should not take BSS."
States important contraindications for prophylactic or therapeutic BSS use.
+ 1 more reference
Avoid routine antibiotic prophylaxis
Action: antibiotic therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antibiotic therapy (NCIT:C15620). NCIT:C15620 is a clinical intervention from the NCI Thesaurus. Ontology label: Antibiotic Therapy NCIT:C15620
Prophylactic antibiotics are not recommended for most travelers because adverse effects, C. difficile infection, microbiome disruption, and acquisition or carriage of antimicrobial-resistant bacteria generally outweigh benefit. They may be considered rarely for short-term travelers who are high-risk hosts.
Show evidence (5 references)
url:https://www.ncbi.nlm.nih.gov/books/NBK620898/ SUPPORT Other
"Prophylactic antibiotics are not recommended for most travelers."
States the current default against routine antibiotic prophylaxis.
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"For almost all travelers, though, the risks associated with the use of prophylactic antibiotics, including side effects, <em>Clostridioides difficile</em> infection, and increased risk of carriage of antimicrobial-resistant bacteria, outweigh the potential benefits. Prophylactic antibiotics..."
Directly supports the adverse-effect, C. difficile, resistant-carriage, and rare high-risk-host qualifications.
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"Prophylactic antibiotics afford no protection against nonbacterial pathogens and can remove normally protective microflora from the bowel, increasing the risk for acquisition of resistant bacterial pathogens."
Directly supports the microbiome-disruption and resistant-pathogen acquisition rationale.
+ 2 more references
Targeted antiprotozoal therapy for giardiasis
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: metronidazole CHEBI:6909 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses metronidazole (CHEBI:6909). CHEBI:6909 is a therapeutic agent from Chemical Entities of Biological Interest. tinidazole CHEBI:63627 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses tinidazole (CHEBI:63627). CHEBI:63627 is a therapeutic agent from Chemical Entities of Biological Interest.
When Giardia is confirmed or strongly suspected as the cause of persistent traveler's diarrhea, organism-directed options include metronidazole, tinidazole, or nitazoxanide; this is not empiric treatment for every acute diarrheal episode.
Mechanism Target:
INHIBITS Protozoal infection associated with persistent traveler's diarrhea — Organism-directed antiprotozoal therapy treats the ongoing Giardia infection represented by this pathogen-conditioned branch.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK620898/ SUPPORT Other
"The most common parasitic cause of TD is <i>Giardia duodenalis</i>, and treatment options include metronidazole, nitazoxanide, and tinidazole."
Identifies Giardia as the main parasitic cause and lists organism-directed treatment options.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK620898/ SUPPORT Other
"The most common parasitic cause of TD is <i>Giardia duodenalis</i>, and treatment options include metronidazole, nitazoxanide, and tinidazole."
Directly supports targeted treatment options for Giardia-associated traveler's diarrhea.
Azithromycin for severe or dysenteric illness
Action: antibiotic therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antibiotic therapy (NCIT:C15620). NCIT:C15620 is a clinical intervention from the NCI Thesaurus. Ontology label: Antibiotic Therapy NCIT:C15620
Agent: azithromycin CHEBI:2955 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses azithromycin (CHEBI:2955). CHEBI:2955 is a therapeutic agent from Chemical Entities of Biological Interest.
Azithromycin is an antibiotic option for moderate to severe disease and can be used for dysentery. Macrolides remain recommended for illness from South Central Asia and are preferred in sub-Saharan Africa because of high fluoroquinolone nonsusceptibility in Campylobacter; empiric therapy after South American exposure warrants closer monitoring because Shigella macrolide resistance and Campylobacter fluoroquinolone resistance pull selection in opposing directions.
Mechanism Target:
INHIBITS Bacterial mRNA Translation by the Ribosome — Azithromycin binds the bacterial 50S ribosomal subunit and inhibits bacterial protein synthesis in susceptible enteropathogens.
Show evidence (1 reference)
PMID:18192791 SUPPORT Other
"This mutation confers resistance by precluding macrolide binding to the bacterial 50S ribosomal subunit, of which 23S rRNA is a structural component."
Establishes the conserved bacterial 50S ribosomal binding target of macrolides.
Show evidence (5 references)
PMID:31084597 SUPPORT Other
"Azithromycin can be used even for the treatment of dysentery whereas fluoroquinolones and rifaximin cannot be used for such purpose."
Directly distinguishes azithromycin as an option for dysenteric disease.
PMID:31084597 SUPPORT Other
"For moderate travelers' diarrhea, antibiotics such as fluoroquinolones, azithromycin, and rifaximin may be used."
Directly supports azithromycin as an antibiotic option for functionally moderate illness.
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"Antibiotic treatment is advised (single-dose regimens may be used): <ul> <li>Azithromycin is preferred</li>"
The current functional-severity table identifies azithromycin as the preferred antibiotic for severe illness.
+ 2 more references
Rifaximin for noninvasive Escherichia coli illness
Action: antibiotic therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antibiotic therapy (NCIT:C15620). NCIT:C15620 is a clinical intervention from the NCI Thesaurus. Ontology label: Antibiotic Therapy NCIT:C15620
Agent: rifaximin CHEBI:75246 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses rifaximin (CHEBI:75246). CHEBI:75246 is a therapeutic agent from Chemical Entities of Biological Interest.
Rifaximin is a nonabsorbed antibiotic option for functionally moderate or severe, non-dysenteric illness only when noninvasive E. coli is the likely cause. It is not indicated for mild illness and is not appropriate for invasive or dysenteric disease.
Mechanism Target:
INHIBITS Bacterial RNA Polymerase (Rifamycin Target) — Rifaximin is a rifamycin derivative that inhibits bacterial RNA polymerase in susceptible noninvasive E. coli.
Show evidence (1 reference)
PMID:32342856 SUPPORT Other
"The most clinically important and extensively studied class of antibiotics known to inhibit bacterial RNAP are the rifamycins."
Directly supports bacterial RNA polymerase as the target of the rifamycin class.
Show evidence (4 references)
PMID:32966000 SUPPORT Other
"Rifaximin is an antibiotic used to treat irritable bowel syndrome with diarrhea, reduce the risk of overt hepatic encephalopathy recurrence in adults, and treat travelers’ diarrhea caused by noninvasive strains of Escherichia coli."
Supports the narrow organism/invasiveness indication for rifaximin.
PMID:31084597 SUPPORT Other
"Azithromycin can be used even for the treatment of dysentery whereas fluoroquinolones and rifaximin cannot be used for such purpose."
Supports exclusion of rifaximin from dysenteric illness.
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"Rifaximin (for moderate, noninvasive diarrhea)"
Directly supports rifaximin for functionally moderate, noninvasive illness.
+ 1 more reference
Rifamycin SV for noninvasive Escherichia coli illness in adults
Action: antibiotic therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antibiotic therapy (NCIT:C15620). NCIT:C15620 is a clinical intervention from the NCI Thesaurus. Ontology label: Antibiotic Therapy NCIT:C15620
Agent: rifamycin SV CHEBI:29673 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses rifamycin SV (CHEBI:29673). CHEBI:29673 is a therapeutic agent from Chemical Entities of Biological Interest.
Rifamycin SV is a nonabsorbed, enteric-coated antibiotic option for selected adults with non-dysenteric traveler's diarrhea caused by noninvasive E. coli. Travelers need clinical evaluation or a separate backup agent if invasive illness develops.
Mechanism Target:
INHIBITS Bacterial RNA Polymerase (Rifamycin Target) — Rifamycin SV inhibits bacterial RNA polymerase in susceptible noninvasive E. coli.
Show evidence (1 reference)
PMID:32342856 SUPPORT Other
"The most clinically important and extensively studied class of antibiotics known to inhibit bacterial RNAP are the rifamycins."
Establishes bacterial RNA polymerase as the conserved rifamycin-class target.
Show evidence (3 references)
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"Another therapeutic option is rifamycin, approved to treat TD caused by noninvasive strains of <em>E. coli</em> in adults."
Establishes the adult, noninvasive-E. coli indication.
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"Two randomized clinical trials showed that rifamycin SV was superior to placebo and noninferior to ciprofloxacin in the treatment of TD."
Summarizes the randomized trial evidence supporting rifamycin SV efficacy.
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"As with rifaximin, travelers taking rifamycin would need to seek medical care or carry a separate antibiotic (e.g., azithromycin) in case of infection due to an invasive pathogen."
Establishes the invasive-disease limitation and backup-treatment requirement.
Fluoroquinolone therapy in selected non-dysenteric cases
Action: antibiotic therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antibiotic therapy (NCIT:C15620). NCIT:C15620 is a clinical intervention from the NCI Thesaurus. Ontology label: Antibiotic Therapy NCIT:C15620
Agent: ciprofloxacin CHEBI:100241 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses ciprofloxacin (CHEBI:100241). CHEBI:100241 is a therapeutic agent from Chemical Entities of Biological Interest.
A fluoroquinolone such as ciprofloxacin can be considered for selected moderate or severe non-dysenteric illness, but high and geographically variable nonsusceptibility substantially constrains empiric use.
Mechanism Target:
INHIBITS DNA Gyrase and Topoisomerase IV (Fluoroquinolone Target) — Fluoroquinolones inhibit bacterial DNA gyrase and topoisomerase IV in susceptible enteropathogens.
Show evidence (1 reference)
PMID:27449972 SUPPORT Other
"Quinolones dually target DNA gyrase and topoisomerase IV binding to specific domains and conformations so as to block DNA strand passage catalysis and stabilize DNA-enzyme complexes that block the DNA replication apparatus and generate double breaks in DNA that underlie their bactericidal activity."
Directly supports inhibition of the bacterial type II topoisomerase target.
Show evidence (3 references)
PMID:31084597 SUPPORT Other
"For moderate travelers' diarrhea, antibiotics such as fluoroquinolones, azithromycin, and rifaximin may be used."
Supports fluoroquinolones as a conditional option for moderate illness.
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"Fluoroquinolones or rifaximin can be used for severe, non-dysenteric diarrhea"
Directly supports fluoroquinolones as a conditional option for severe, non-dysenteric illness.
PMID:41591385 SUPPORT Human Clinical
"Among Campylobacter isolates, nonsusceptibility to fluoroquinolones was found in 206 of 274 isolates (75%; 95% CI, 70%-80%), and nonsusceptibility to macrolides was found in 30 of 255 isolates (12%; 95% CI, 8%-16%) and was highest in travelers to South Central Asia (45 of 51 isolates; 88%; 95%..."
Quantifies the resistance constraint that limits empiric fluoroquinolone use, especially for Campylobacter.
🌍

Environmental Factors

2
Exposure to fecally contaminated water during travel
exposure to contaminated water ECTO:7000119 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to contaminated water (ECTO:7000119). ECTO:7000119 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Drinking or consuming water contaminated by feces exposes travelers to enteric pathogens.
Show evidence (1 reference)
PMID:31084597 SUPPORT Other
"Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces."
Directly supports contaminated water as a traveler's diarrhea exposure.
Mechanism Target:
TRIGGERS ETEC colonization-factor adhesion to small-intestinal enterocytes — When contaminated water carries viable ETEC, ingestion and passage to the small intestine precede epithelial adhesion.
Show evidence (1 reference)
PMID:31084597 SUPPORT Other
"Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces."
Establishes fecally contaminated water ingestion as an upstream acquisition route.
TRIGGERS Shigella invasion of the colonic epithelium — When contaminated water carries viable Shigella, ingestion and gastrointestinal transit precede colonic epithelial invasion.
Show evidence (1 reference)
PMID:21413292 SUPPORT Other
"Shigellosis also presents a significant risk to travelers from developed countries when visiting in endemic areas, and sporadic food or water-borne outbreaks occur in developed countries."
Supports travel risk and food- or water-borne acquisition upstream of Shigella invasion.
TRIGGERS Protozoal infection associated with persistent traveler's diarrhea — When contaminated water carries viable protozoa, ingestion and gastrointestinal transit precede intestinal infection.
Show evidence (1 reference)
PMID:31084597 SUPPORT Other
"Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces."
Establishes fecally contaminated water ingestion as an upstream acquisition route for the heterogeneous syndrome.
Exposure to fecally contaminated food during travel
Eating food contaminated by feces exposes travelers to enteric pathogens.
Show evidence (1 reference)
PMID:31084597 SUPPORT Other
"Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces."
Directly supports contaminated food as a traveler's diarrhea exposure.
Mechanism Target:
TRIGGERS ETEC colonization-factor adhesion to small-intestinal enterocytes — When contaminated food carries viable ETEC, ingestion and passage to the small intestine precede epithelial adhesion.
Show evidence (1 reference)
PMID:31084597 SUPPORT Other
"Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces."
Establishes fecally contaminated food ingestion as an upstream acquisition route.
TRIGGERS Shigella invasion of the colonic epithelium — When contaminated food carries viable Shigella, ingestion and gastrointestinal transit precede colonic epithelial invasion.
Show evidence (1 reference)
PMID:21413292 SUPPORT Other
"Shigellosis also presents a significant risk to travelers from developed countries when visiting in endemic areas, and sporadic food or water-borne outbreaks occur in developed countries."
Supports travel risk and food- or water-borne acquisition upstream of Shigella invasion.
TRIGGERS Protozoal infection associated with persistent traveler's diarrhea — When contaminated food carries viable protozoa, ingestion and gastrointestinal transit precede intestinal infection.
Show evidence (1 reference)
PMID:31084597 SUPPORT Other
"Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces."
Establishes fecally contaminated food ingestion as an upstream acquisition route for the heterogeneous syndrome.
🔬

Diagnosis

6
Selective pathogen testing in severe, dysenteric, or high-risk illness
Pathogen-directed testing is most important for severe or bloody diarrhea and for patients at increased risk of a severe course; routine testing is not implied for every self-limited episode.
Diagnostic Procedure NCIT:C18020 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:39879968 SUPPORT Other
"Pathogen diagnostics are indicated for severe or dysenteric courses as well as for increased risk of severe courses."
Directly supports severity- and risk-based selection for pathogen testing.
Stool culture with organism-directed PCR, antigen, or microscopy testing
Stool culture is central when pathogen identification is indicated and can be supplemented by PCR, antigen testing, or microscopy according to the suspected organism and illness duration.
Show evidence (1 reference)
PMID:39879968 SUPPORT Other
"A central component of pathogen diagnostics is stool culture. To detect specific pathogens, this is expanded to include stool microscopy, PCR, and antigen diagnostics."
Establishes stool culture as the central diagnostic component and supports organism-directed microscopy, PCR, and antigen testing.
Polymerase chain reaction testing of stool
Molecular testing can detect pathogen nucleic acids when targeted or multiplex assays are clinically appropriate.
Polymerase Chain Reaction NCIT:C17003 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:39879968 SUPPORT Other
"To detect specific pathogens, this is expanded to include stool microscopy, PCR, and antigen diagnostics."
Supports PCR as a clinically directed pathogen-detection method rather than only as a surveillance assay.
Culture-based antimicrobial susceptibility testing when possible
Culture and susceptibility testing can guide therapy and preserve regional resistance surveillance, including after an initial culture-independent pathogen result.
Diagnostic Procedure NCIT:C18020 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:41591385 SUPPORT Human Clinical
"Antimicrobial susceptibility from culture should be obtained when possible, including after pathogen detection by culture-independent methods."
Directly supports culture-based susceptibility testing in the setting of geographically variable resistance.
Blood culture and malaria evaluation for a febrile returning traveler
Fever after travel broadens the evaluation beyond uncomplicated diarrhea; blood culture and exposure-directed malaria testing are important red-flag investigations.
Diagnostic Procedure NCIT:C18020 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:39879968 SUPPORT Other
"If there is a fever, a blood culture and, depending on exposure, malaria diagnosis should be carried out."
Directly supports blood culture and exposure-dependent malaria evaluation in febrile illness after travel.
Protozoal evaluation for persistent diarrhea
Persistent or chronic diarrhea during or after travel warrants targeted examination for Giardia, Entamoeba, Cryptosporidium, Cyclospora, and other intestinal protozoa using organism-appropriate microscopy, antigen, or PCR methods.
Diagnostic Procedure NCIT:C18020 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:11389503 SUPPORT Other
"Evaluation of the traveler with chronic diarrhea should include a careful examination for typical infecting organisms, such as Giardia and Entamoeba species, as well as for emerging parasites, such as Cryptosporidium species, Cyclospora species, and microsporidia."
Directly supports a broad protozoal work-up for chronic post-travel diarrhea.
📈

Progression

5
Toxin-mediated foodborne illness
Duration: 12-24 hours Incubation: Within a few hours days
This rapid-onset phase applies to toxin-mediated illness and not to every cause of traveler's diarrhea.
Show evidence (2 references)
url:https://www.ncbi.nlm.nih.gov/books/NBK620898/ SUPPORT Other
"Toxin-mediated illness, for example, generally causes symptoms within a few hours."
Establishes the characteristic rapid onset of toxin-mediated illness.
PMID:41818528 SUPPORT Other
"In toxin-mediated illness, both vomiting and diarrhea can be present; symptoms usually resolve spontaneously within 12–24 hours."
Provides the typical short duration of toxin-mediated illness.
Acute bacterial traveler's diarrhea
Duration: 3-7 days Incubation: 0.25-4 (6-96 hours) days
These intervals are bacterial-pathogen conditioned and should not be applied to protozoal disease.
Show evidence (2 references)
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"By contrast, illnesses caused by bacterial and viral pathogens have incubation periods of 6&ndash;96 hours."
Provides the bacterial and viral incubation interval.
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"Untreated, bacterial diarrhea usually lasts 3&ndash;7 days."
Provides the usual untreated bacterial duration.
Acute viral traveler's diarrhea
Duration: 2-3 days Incubation: 0.25-4 (6-96 hours) days
These intervals are viral-pathogen conditioned and should not be applied to protozoal disease.
Show evidence (2 references)
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"By contrast, illnesses caused by bacterial and viral pathogens have incubation periods of 6&ndash;96 hours."
Provides the bacterial and viral incubation interval.
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"Viral diarrhea generally lasts 2&ndash;3 days."
Provides the usual viral duration.
Protozoal traveler's diarrhea
Duration: Weeks to months without treatment Incubation: 7-14 days
Protozoal disease often presents later than bacterial or viral disease and can be persistent.
Show evidence (2 references)
url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html SUPPORT Other
"In general, illnesses due to protozoal pathogens have longer incubation periods (1&ndash;2 weeks), rarely presenting in the first few days of travel."
Provides the longer incubation interval for protozoal disease.
url:https://www.ncbi.nlm.nih.gov/books/NBK620898/ SUPPORT Other
"Protozoal diarrhea can persist for weeks to months without treatment."
Provides the potential untreated duration of protozoal disease.
Post-infectious irritable bowel syndrome
Duration: Mean 15 months in a retrospective referral-center cohort
This persistent phase affects a subset after the acute infection and should not be treated as the usual course.
Show evidence (1 reference)
PMID:36881659 SUPPORT Human Clinical
"The symptoms persisted for a mean of 15 months after diagnosis and treatment of TD."
Provides observed duration for persistent PI-IBS symptoms in a selected clinical cohort.
📊

Prevalence

1
International travelers during a 2-week travel period
Unknown 30000–70000 per 100,000 >1 in 1,000
The source reports a destination- and season-dependent 30%-70% attack proportion over two weeks. The schema has no attack-rate measure, so measure_type is explicitly UNKNOWN; the bounds are normalized to 30,000-70,000 affected travelers per 100,000.
Show evidence (1 reference)
PMID:41818528 SUPPORT Other
"Attack rates range from 30% to 70% of travelers during a 2-week period, depending on the destination and season of travel."
Provides a current, time-bounded attack-proportion range and identifies destination and season dependence.
🌍

Epidemiology

3
Bacterial etiologic share
Bacterial enteropathogens account for most episodes, but the responsible species and pathotypes vary by destination and diagnostic method.
75–90 percent of cases
Show evidence (1 reference)
PMID:41818528 SUPPORT Other
"Bacteria are the predominant enteropathogens and are thought to account for ≥75%–90% of cases."
Provides the current estimated bacterial share of the syndrome.
Viral etiologic share
Intestinal viruses are a substantial and likely underdetected component, particularly when molecular assays are used.
10–25 percent of illnesses
Show evidence (1 reference)
PMID:41818528 SUPPORT Other
"Intestinal viruses account for at least 10%–25% of illnesses and are more commonly associated with vomiting."
Provides the estimated viral share and its association with vomiting.
Protozoal etiologic share in longer-term travelers
Protozoal pathogens contribute a minority of diagnoses and tend to present later, especially in longer-term travelers.
10–10 approximate percent of diagnoses
Show evidence (1 reference)
PMID:41818528 SUPPORT Other
"Infections with protozoal pathogens are slower to manifest symptoms and collectively account for approximately 10% of diagnoses, predominantly in longer-term travelers (see Post-Travel Diarrhea)."
Quantifies and temporally contextualizes the protozoal contribution.
🦠

Infectious Agent

8
Enterotoxigenic Escherichia coli
ETEC is an important diarrheagenic E. coli pathotype. NCBITaxon:562 represents the species rather than the narrower enterotoxigenic pathotype, which is retained in this free-text name.
Escherichia coli NCBITaxon:562 NCBI Taxonomy (NCBITaxon)
Show evidence (1 reference)
PMID:35247581 SUPPORT Other
"Diarrhoeagenic Escherichia coli (DEC) continue to be the most commonly implicated bacteria in TD, although Enteropathogenic E. coli (EPEC) and Enteroaggregative E. coli (EAEC) now appear to be predominant where Enterotoxigenic E. coli (ETEC) was previously considered most prevalent globally."
Supports ETEC as an important cause while showing why it should not be represented as the universally predominant pathogen.
Enteroaggregative Escherichia coli
EAEC is a diarrheagenic E. coli pathotype increasingly identified in traveler's diarrhea. NCBITaxon:562 represents the species rather than the narrower enteroaggregative pathotype, which is retained in this free-text name.
Escherichia coli NCBITaxon:562 NCBI Taxonomy (NCBITaxon)
Show evidence (1 reference)
PMID:35247581 SUPPORT Other
"Diarrhoeagenic Escherichia coli (DEC) continue to be the most commonly implicated bacteria in TD, although Enteropathogenic E. coli (EPEC) and Enteroaggregative E. coli (EAEC) now appear to be predominant where Enterotoxigenic E. coli (ETEC) was previously considered most prevalent globally."
Directly supports EAEC as a major contemporary diarrheagenic E. coli pathotype in traveler's diarrhea.
Enteropathogenic Escherichia coli
EPEC is a diarrheagenic E. coli pathotype increasingly identified in traveler's diarrhea. NCBITaxon:562 represents the species rather than the narrower enteropathogenic pathotype, which is retained in this free-text name.
Escherichia coli NCBITaxon:562 NCBI Taxonomy (NCBITaxon)
Show evidence (1 reference)
PMID:35247581 SUPPORT Other
"Diarrhoeagenic Escherichia coli (DEC) continue to be the most commonly implicated bacteria in TD, although Enteropathogenic E. coli (EPEC) and Enteroaggregative E. coli (EAEC) now appear to be predominant where Enterotoxigenic E. coli (ETEC) was previously considered most prevalent globally."
Directly supports EPEC as a major contemporary diarrheagenic E. coli pathotype in traveler's diarrhea.
Norovirus
Norovirus NCBITaxon:142786 NCBI Taxonomy (NCBITaxon)
Show evidence (1 reference)
PMID:39530798 SUPPORT Human Clinical
"Harmonized laboratory methods conducted at each partner institution identified >1 pathogens, including Escherichia coli (67%-82%), norovirus (4%-29%), and Campylobacter jejuni (2%-20%), in 403 (79%) cases."
Multisite molecular surveillance directly detected norovirus in travelers with acute gastrointestinal illness.
Campylobacter jejuni
Campylobacter jejuni NCBITaxon:197 NCBI Taxonomy (NCBITaxon)
Show evidence (1 reference)
PMID:39530798 SUPPORT Human Clinical
"Harmonized laboratory methods conducted at each partner institution identified >1 pathogens, including Escherichia coli (67%-82%), norovirus (4%-29%), and Campylobacter jejuni (2%-20%), in 403 (79%) cases."
Multisite molecular surveillance directly detected C. jejuni in travelers with acute gastrointestinal illness.
Shigella species
Shigella NCBITaxon:620 NCBI Taxonomy (NCBITaxon)
Show evidence (1 reference)
PMID:41591385 SUPPORT Human Clinical
"The invasive bacterial pathogens Campylobacter species, Shigella species, and nontyphoidal Salmonella (NTS) species, as well as diarrheagenic strains of Escherichia coli, are responsible for the majority of cases of travel-associated bacterial diarrhea."
Identifies Shigella among the major invasive causes of travel-associated bacterial diarrhea.
Nontyphoidal Salmonella enterica
Salmonella enterica NCBITaxon:28901 NCBI Taxonomy (NCBITaxon)
Show evidence (1 reference)
PMID:41591385 SUPPORT Human Clinical
"The invasive bacterial pathogens Campylobacter species, Shigella species, and nontyphoidal Salmonella (NTS) species, as well as diarrheagenic strains of Escherichia coli, are responsible for the majority of cases of travel-associated bacterial diarrhea."
Identifies nontyphoidal Salmonella among the major invasive causes of travel-associated bacterial diarrhea.
Giardia duodenalis
Giardia duodenalis NCBITaxon:5741 NCBI Taxonomy (NCBITaxon)
Show evidence (1 reference)
PMID:36881659 SUPPORT Human Clinical
"A microbiological diagnosis of TD was made in 32 of these 68 (47%) patients, 24 (75%) of whom had a parasitic infection, Giardia duodenalis being the most commonly detected parasite (n = 20, 83.3%)."
Supports Giardia as a travel-associated cause particularly relevant to persistent gastrointestinal illness.
⚖️

Clinical Burden

Variable
Most illness is self-limited, but functional impact is material in a subset, with interrupted activities and occasional hospitalization; dehydration, dysentery, and persistent PI-IBS add further burden in selected cases.
Show evidence (1 reference)
PMID:28719282 SUPPORT Human Clinical
"Of 172 with TD during travel, 24% stopped planned activities, and 2% were hospitalized."
Quantifies functional disruption and occasional hospitalization in a prospective traveler cohort.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Traveler's Diarrhea:

Post-infectious irritable bowel syndrome MONDO:0005052
Overlapping Features Persistent gastrointestinal symptoms can continue after the acute infection has cleared and may represent PI-IBS rather than ongoing enteric infection.
Distinguishing Features
  • Persistent symptoms after pathogen clearance favor a postinfectious process over active infection.
Show evidence (1 reference)
PMID:21180583 SUPPORT Other
"Postinfectious processes represent a second cause and comprise temporary lactose malabsorption and postinfectious irritable bowel syndrome, now considered a major cause of persistent TD."
Establishes PI-IBS as a major noninfectious explanation for persistent symptoms after traveler's diarrhea.
Inflammatory bowel disease unmasked after traveler's diarrhea Not Yet Curated MONDO:0005265
Overlapping Features An incident chronic inflammatory bowel disorder can first become apparent after an acute travel-associated diarrheal episode and should not be assumed to represent persistent infection.
Distinguishing Features
  • Evidence of chronic intestinal inflammation despite an unrevealing infectious work-up favors inflammatory bowel disease.
Show evidence (1 reference)
PMID:21180583 SUPPORT Other
"Finally, apparently unrelated chronic diseases causing diarrhea are occasionally unmasked by TD and represent a third type of persistent TD, among which the well established case of incident inflammatory bowel disease poses intriguing pathogenesis questions."
Directly identifies incident inflammatory bowel disease as a chronic disorder that can be unmasked by traveler's diarrhea.
Clostridioides difficile colitis after antimicrobial exposure MONDO:0000705
Overlapping Features C. difficile colitis is an important alternative explanation for persistent or recurrent diarrhea after antibiotics taken during travel.
Distinguishing Features
  • Recent antimicrobial exposure increases concern for C. difficile colitis.
Show evidence (1 reference)
PMID:9658255 SUPPORT Other
"If the patient is immunocompromised, microsporidia and Isospora become more likely, and a prior history of antimicrobial use raises the possibility of C. difficile colitis."
Directly supports C. difficile colitis as an antibiotic-associated cause to consider in the returned traveler.
📊

Related Datasets

1
The MAIT cell response to controlled oral enterotoxigenic E. coli challenge geo:GSE276378
Mucosa-associated invariant T (MAIT) cells recognize conserved microbial antigens presented by MR1 and contribute to barrier immunity. This human controlled ETEC challenge dataset profiles blood responses, with activation and proliferation most evident among participants who developed mild to severe diarrhea.
human BULK RNA SEQ n=28
PMID:40713903
Accession, title, sample count, organism, and direct ETEC challenge relevance were verified against GEO metadata. The previous aEPEC epithelial-cell dataset was removed because it was not a traveler's-diarrhea cohort or ETEC model.
🧫

Experimental Models

1
Human and mouse intestinal enteroid ST-secretion model ORGANOID
Three-dimensional ex vivo intestinal enteroids derived from mouse and human epithelium express the GUCY2C secretory axis. Heat-stable ETEC enterotoxin produces quantifiable luminal fluid accumulation through GUCY2C-cGMP-PKG-CFTR signaling, and pharmacologic CFTR inhibition abrogates secretion.
heat-stable ETEC enterotoxin challenge linaclotide secretagogue challenge pharmacologic CFTR inhibition
Cell source
Human and mouse intestinal epithelium
Culture
Three-dimensional ex vivo intestinal enteroids with luminal fluid-accumulation imaging
Publication
PMID:27481254
Pathograph links
GUCY2C-dependent cGMP production recapitulates fidelity: moderate The enteroids retain the canonical GUCY2C-to-cGMP-to-PKG signaling axis needed for heat-stable-enterotoxin secretion.
Limitations: This is an ex vivo toxin-challenge system rather than intact pathogen infection and does not reproduce immune, microbiota, vascular, systemic, or travel-exposure compartments; it combines observations from two species.
Show evidence (1 reference)
PMID:27481254 SUPPORT In Vitro
"Enteroid secretion depended on canonical molecular signaling events responsible for ETEC-induced diarrhea, including cyclic GMP (cGMP) produced by GUCY2C, activation of cGMP-dependent protein kinase (PKG), and opening of the cystic fibrosis transmembrane conductance regulator (CFTR)."
Connects the model directly to the GUCY2C-cGMP-PKG secretory branch.
Net intestinal electrolyte and water secretion recapitulates fidelity: moderate Heat-stable enterotoxin produces quantifiable fluid accumulation within enteroid lumens, recapitulating the net secretory output of ETEC disease.
Limitations: Luminal volume is a tissue-level epithelial secretion readout in an ex vivo toxin challenge; it does not model whole-organism stool output, hydration status, immune responses, microbiota, or intact infection.
Readouts
Enteroid luminal fluid accumulation after heat-stable enterotoxin
Direction: INCREASED
Interpretation: Increased enteroid-lumen volume is the functional readout of toxin-induced epithelial secretion.
Show evidence (1 reference)
PMID:27481254 SUPPORT In Vitro
"ST and its structural analog, linaclotide, an FDA-approved oral secretagog, induced fluid accumulation quantified simultaneously in scores of enteroid lumens, recapitulating ETEC-induced intestinal secretion."
Directly defines the model's quantitative luminal-fluid readout.
Show evidence (1 reference)
PMID:27481254 SUPPORT In Vitro
"ST and its structural analog, linaclotide, an FDA-approved oral secretagog, induced fluid accumulation quantified simultaneously in scores of enteroid lumens, recapitulating ETEC-induced intestinal secretion."
Directly supports the model's tissue-level secretory output.
CFTR-mediated epithelial chloride secretion recapitulates fidelity: moderate CFTR opening is required for the enteroid secretory response, and pharmacologic CFTR inhibition rescues the fluid-accumulation readout.
Limitations: CFTR inhibition demonstrates pathway dependence in an epithelial ex vivo model but does not establish safety or efficacy of an antidiarrheal therapy in travelers.
Readouts
Abrogation of enterotoxin-induced fluid secretion by CFTR inhibition
Direction: ABOLISHED
Interpretation: Loss of luminal fluid accumulation after CFTR inhibition shows that the modeled secretory output depends on CFTR.
Show evidence (1 reference)
PMID:27481254 SUPPORT In Vitro
"Importantly, pharmacological inhibition of CFTR abrogated enteroid fluid secretion, providing proof of concept for the utility of this model to screen antidiarrheal agents."
Directly reports rescue of the fluid-secretion phenotype by CFTR inhibition.
Show evidence (1 reference)
PMID:27481254 SUPPORT In Vitro
"Importantly, pharmacological inhibition of CFTR abrogated enteroid fluid secretion, providing proof of concept for the utility of this model to screen antidiarrheal agents."
Establishes CFTR dependence and the model's experimental rescue response.
Show evidence (1 reference)
PMID:27481254 SUPPORT In Vitro
"Here, we reveal that mouse and human intestinal enteroids in three-dimensional ex vivo cultures express the components of the GUCY2C secretory signaling axis."
Directly establishes the species, culture system, and modeled signaling-axis components.
{ }

Source YAML

click to show 
name: Traveler's Diarrhea
creation_date: '2025-12-19T01:18:09Z'
description: >-
  Traveler's diarrhea is an acute infectious gastrointestinal syndrome acquired
  during or soon after travel, usually through ingestion of food or water
  contaminated with fecal pathogens. It is etiologically heterogeneous:
  diarrheagenic Escherichia coli pathotypes, Campylobacter, Shigella,
  Salmonella, norovirus, and protozoa contribute in proportions that vary by
  destination and diagnostic method. Most illness is self-limited diarrhea,
  but fever, bloody diarrhea, dehydration, and persistent postinfectious
  symptoms can occur. The mechanistic graph below uses enterotoxigenic E. coli
  (ETEC) as a well-supported exemplar of noninvasive secretory disease rather
  than as a mechanism shared by every cause of the syndrome.
category: Infectious Disease
disease_term:
  preferred_term: traveler's diarrhea
  term:
    id: MONDO:0001673
    label: diarrheal disease
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0001673
      label: diarrheal disease
    mapping_predicate: skos:closeMatch
    mapping_source: MONDO
    mapping_justification: >-
      Closest MONDO parent term available for traveler's diarrhea in the local
      ontology snapshot.
parents:
- Infectious diarrhea
- Travel-related infections
infectious_agent:
- name: Enterotoxigenic Escherichia coli
  description: >-
    ETEC is an important diarrheagenic E. coli pathotype. NCBITaxon:562
    represents the species rather than the narrower enterotoxigenic pathotype,
    which is retained in this free-text name.
  infectious_agent_term:
    preferred_term: Escherichia coli
    term:
      id: NCBITaxon:562
      label: Escherichia coli
  evidence:
  - reference: PMID:35247581
    reference_title: "Bacterial travellers' diarrhoea: A narrative review of literature published over the past 10 years."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Diarrhoeagenic Escherichia coli (DEC) continue to be the most commonly
      implicated bacteria in TD, although Enteropathogenic E. coli (EPEC) and
      Enteroaggregative E. coli (EAEC) now appear to be predominant where
      Enterotoxigenic E. coli (ETEC) was previously considered most prevalent
      globally.
    explanation: >-
      Supports ETEC as an important cause while showing why it should not be
      represented as the universally predominant pathogen.
- name: Enteroaggregative Escherichia coli
  description: >-
    EAEC is a diarrheagenic E. coli pathotype increasingly identified in
    traveler's diarrhea. NCBITaxon:562 represents the species rather than the
    narrower enteroaggregative pathotype, which is retained in this free-text
    name.
  infectious_agent_term:
    preferred_term: Escherichia coli
    term:
      id: NCBITaxon:562
      label: Escherichia coli
  evidence:
  - reference: PMID:35247581
    reference_title: "Bacterial travellers' diarrhoea: A narrative review of literature published over the past 10 years."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Diarrhoeagenic Escherichia coli (DEC) continue to be the most commonly
      implicated bacteria in TD, although Enteropathogenic E. coli (EPEC) and
      Enteroaggregative E. coli (EAEC) now appear to be predominant where
      Enterotoxigenic E. coli (ETEC) was previously considered most prevalent
      globally.
    explanation: Directly supports EAEC as a major contemporary diarrheagenic E. coli pathotype in traveler's diarrhea.
- name: Enteropathogenic Escherichia coli
  description: >-
    EPEC is a diarrheagenic E. coli pathotype increasingly identified in
    traveler's diarrhea. NCBITaxon:562 represents the species rather than the
    narrower enteropathogenic pathotype, which is retained in this free-text
    name.
  infectious_agent_term:
    preferred_term: Escherichia coli
    term:
      id: NCBITaxon:562
      label: Escherichia coli
  evidence:
  - reference: PMID:35247581
    reference_title: "Bacterial travellers' diarrhoea: A narrative review of literature published over the past 10 years."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Diarrhoeagenic Escherichia coli (DEC) continue to be the most commonly
      implicated bacteria in TD, although Enteropathogenic E. coli (EPEC) and
      Enteroaggregative E. coli (EAEC) now appear to be predominant where
      Enterotoxigenic E. coli (ETEC) was previously considered most prevalent
      globally.
    explanation: Directly supports EPEC as a major contemporary diarrheagenic E. coli pathotype in traveler's diarrhea.
- name: Norovirus
  infectious_agent_term:
    preferred_term: Norovirus
    term:
      id: NCBITaxon:142786
      label: Norovirus
  evidence:
  - reference: PMID:39530798
    reference_title: "Etiology and Epidemiology of Travelers' Diarrhea among US Military and Adult Travelers, 2018-2023."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Harmonized laboratory methods conducted at each partner institution
      identified >1 pathogens, including Escherichia coli (67%-82%), norovirus
      (4%-29%), and Campylobacter jejuni (2%-20%), in 403 (79%) cases.
    explanation: Multisite molecular surveillance directly detected norovirus in travelers with acute gastrointestinal illness.
- name: Campylobacter jejuni
  infectious_agent_term:
    preferred_term: Campylobacter jejuni
    term:
      id: NCBITaxon:197
      label: Campylobacter jejuni
  evidence:
  - reference: PMID:39530798
    reference_title: "Etiology and Epidemiology of Travelers' Diarrhea among US Military and Adult Travelers, 2018-2023."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Harmonized laboratory methods conducted at each partner institution
      identified >1 pathogens, including Escherichia coli (67%-82%), norovirus
      (4%-29%), and Campylobacter jejuni (2%-20%), in 403 (79%) cases.
    explanation: Multisite molecular surveillance directly detected C. jejuni in travelers with acute gastrointestinal illness.
- name: Shigella species
  infectious_agent_term:
    preferred_term: Shigella
    term:
      id: NCBITaxon:620
      label: Shigella
  evidence:
  - reference: PMID:41591385
    reference_title: "GeoSentinel Analysis of Travelers' Diarrhea Antimicrobial Resistance Patterns."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The invasive bacterial pathogens Campylobacter species, Shigella species,
      and nontyphoidal Salmonella (NTS) species, as well as diarrheagenic strains
      of Escherichia coli, are responsible for the majority of cases of
      travel-associated bacterial diarrhea.
    explanation: Identifies Shigella among the major invasive causes of travel-associated bacterial diarrhea.
- name: Nontyphoidal Salmonella enterica
  infectious_agent_term:
    preferred_term: Salmonella enterica
    term:
      id: NCBITaxon:28901
      label: Salmonella enterica
  evidence:
  - reference: PMID:41591385
    reference_title: "GeoSentinel Analysis of Travelers' Diarrhea Antimicrobial Resistance Patterns."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The invasive bacterial pathogens Campylobacter species, Shigella species,
      and nontyphoidal Salmonella (NTS) species, as well as diarrheagenic strains
      of Escherichia coli, are responsible for the majority of cases of
      travel-associated bacterial diarrhea.
    explanation: Identifies nontyphoidal Salmonella among the major invasive causes of travel-associated bacterial diarrhea.
- name: Giardia duodenalis
  infectious_agent_term:
    preferred_term: Giardia duodenalis
    term:
      id: NCBITaxon:5741
      label: Giardia duodenalis
  evidence:
  - reference: PMID:36881659
    reference_title: "Post-infectious irritable bowel syndrome following a diagnosis of traveller's diarrhoea: a comprehensive characterization of clinical and laboratory parameters."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A microbiological diagnosis of TD was made in 32 of these 68 (47%)
      patients, 24 (75%) of whom had a parasitic infection, Giardia duodenalis
      being the most commonly detected parasite (n = 20, 83.3%).
    explanation: Supports Giardia as a travel-associated cause particularly relevant to persistent gastrointestinal illness.
prevalence:
- population: International travelers during a 2-week travel period
  measure_type: UNKNOWN
  prevalence_class: ABOVE_1_IN_1000
  rate_low: 30000
  rate_high: 70000
  notes: >-
    The source reports a destination- and season-dependent 30%-70% attack
    proportion over two weeks. The
    schema has no attack-rate measure, so measure_type is explicitly UNKNOWN;
    the bounds are normalized to 30,000-70,000 affected travelers per 100,000.
  evidence:
  - reference: PMID:41818528
    reference_title: Travelers’ Diarrhea.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Attack rates range from 30% to 70% of travelers during a 2-week period, depending on the destination and season of travel.
    explanation: Provides a current, time-bounded attack-proportion range and identifies destination and season dependence.
epidemiology:
- name: Bacterial etiologic share
  description: Bacterial enteropathogens account for most episodes, but the responsible species and pathotypes vary by destination and diagnostic method.
  minimum_value: 75
  maximum_value: 90
  unit: percent of cases
  evidence:
  - reference: PMID:41818528
    reference_title: Travelers’ Diarrhea.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Bacteria are the predominant enteropathogens and are thought to account for ≥75%–90% of cases.
    explanation: Provides the current estimated bacterial share of the syndrome.
- name: Viral etiologic share
  description: Intestinal viruses are a substantial and likely underdetected component, particularly when molecular assays are used.
  minimum_value: 10
  maximum_value: 25
  unit: percent of illnesses
  evidence:
  - reference: PMID:41818528
    reference_title: Travelers’ Diarrhea.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Intestinal viruses account for at least 10%–25% of illnesses and are more commonly associated with vomiting.
    explanation: Provides the estimated viral share and its association with vomiting.
- name: Protozoal etiologic share in longer-term travelers
  description: Protozoal pathogens contribute a minority of diagnoses and tend to present later, especially in longer-term travelers.
  minimum_value: 10
  maximum_value: 10
  unit: approximate percent of diagnoses
  evidence:
  - reference: PMID:41818528
    reference_title: Travelers’ Diarrhea.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Infections with protozoal pathogens are slower to manifest symptoms and collectively account for approximately 10% of diagnoses, predominantly in longer-term travelers (see Post-Travel Diarrhea).
    explanation: Quantifies and temporally contextualizes the protozoal contribution.
progression:
- phase: Toxin-mediated foodborne illness
  incubation_days: Within a few hours
  duration: 12-24 hours
  notes: This rapid-onset phase applies to toxin-mediated illness and not to every cause of traveler's diarrhea.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK620898/
    reference_title: "Travelers’ Diarrhea - CDC Yellow Book, 2026 edition - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Toxin-mediated illness, for example, generally causes symptoms within a few hours.
    explanation: Establishes the characteristic rapid onset of toxin-mediated illness.
  - reference: PMID:41818528
    reference_title: Travelers’ Diarrhea.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: In toxin-mediated illness, both vomiting and diarrhea can be present; symptoms usually resolve spontaneously within 12–24 hours.
    explanation: Provides the typical short duration of toxin-mediated illness.
- phase: Acute bacterial traveler's diarrhea
  incubation_days: 0.25-4 (6-96 hours)
  duration_days: 3-7
  notes: These intervals are bacterial-pathogen conditioned and should not be applied to protozoal disease.
  evidence:
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: By contrast, illnesses caused by bacterial and viral pathogens have incubation periods of 6&ndash;96 hours.
    explanation: Provides the bacterial and viral incubation interval.
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Untreated, bacterial diarrhea usually lasts 3&ndash;7 days.
    explanation: Provides the usual untreated bacterial duration.
- phase: Acute viral traveler's diarrhea
  incubation_days: 0.25-4 (6-96 hours)
  duration_days: 2-3
  notes: These intervals are viral-pathogen conditioned and should not be applied to protozoal disease.
  evidence:
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: By contrast, illnesses caused by bacterial and viral pathogens have incubation periods of 6&ndash;96 hours.
    explanation: Provides the bacterial and viral incubation interval.
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Viral diarrhea generally lasts 2&ndash;3 days.
    explanation: Provides the usual viral duration.
- phase: Protozoal traveler's diarrhea
  incubation_days: 7-14
  duration: Weeks to months without treatment
  notes: Protozoal disease often presents later than bacterial or viral disease and can be persistent.
  evidence:
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: In general, illnesses due to protozoal pathogens have longer incubation periods (1&ndash;2 weeks), rarely presenting in the first few days of travel.
    explanation: Provides the longer incubation interval for protozoal disease.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK620898/
    reference_title: "Travelers’ Diarrhea - CDC Yellow Book, 2026 edition - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Protozoal diarrhea can persist for weeks to months without treatment.
    explanation: Provides the potential untreated duration of protozoal disease.
- phase: Post-infectious irritable bowel syndrome
  duration: Mean 15 months in a retrospective referral-center cohort
  notes: This persistent phase affects a subset after the acute infection and should not be treated as the usual course.
  evidence:
  - reference: PMID:36881659
    reference_title: "Post-infectious irritable bowel syndrome following a diagnosis of traveller's diarrhoea: a comprehensive characterization of clinical and laboratory parameters."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The symptoms persisted for a mean of 15 months after diagnosis and treatment of TD.
    explanation: Provides observed duration for persistent PI-IBS symptoms in a selected clinical cohort.
clinical_burden:
  burden_level: VARIABLE
  rationale: >-
    Most illness is self-limited, but functional impact is material in a subset,
    with interrupted activities and occasional hospitalization; dehydration,
    dysentery, and persistent PI-IBS add further burden in selected cases.
  evidence:
  - reference: PMID:28719282
    reference_title: "Travelers' Diarrhea and Other Gastrointestinal Symptoms Among Boston-Area International Travelers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of 172 with TD during travel, 24% stopped planned activities, and 2% were hospitalized.
    explanation: Quantifies functional disruption and occasional hospitalization in a prospective traveler cohort.
pathophysiology:
- name: ETEC colonization-factor adhesion to small-intestinal enterocytes
  description: >-
    In the ETEC subset of traveler's diarrhea, bacterial colonization factors
    bind receptors on small-intestinal enterocytes and establish close epithelial
    colonization, positioning toxin-producing organisms at the mucosal surface.
  role: initiating mechanism
  cell_types:
  - preferred_term: enterocyte of epithelium of small intestine
    term:
      id: CL:1000334
      label: enterocyte of epithelium of small intestine
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  biological_processes:
  - preferred_term: adhesion of symbiont to host cell
    term:
      id: GO:0044650
      label: adhesion of symbiont to host cell
  downstream:
  - target: Heat-stable enterotoxin activation of epithelial GUCY2C
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Colonization places ST-producing ETEC at the epithelial surface; toxin production and release are omitted intermediates.
  - target: Heat-labile enterotoxin activation of epithelial G protein-adenylyl cyclase
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Colonization places LT-producing ETEC at the epithelial surface; toxin production, release, and uptake are omitted intermediates.
  evidence:
  - reference: PMID:35358002
    reference_title: "Enterotoxigenic Escherichia coli: intestinal pathogenesis mechanisms and colonization resistance by gut microbiota."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      ETEC is characterized by the ability to produce major virulence factors
      including colonization factors (CFs) and enterotoxins, that bind to specific
      receptors on epithelial cells and induce diarrhea.
    explanation: Supports receptor-binding colonization factors as part of ETEC epithelial pathogenesis.
- name: Heat-stable enterotoxin activation of epithelial GUCY2C
  description: >-
    ETEC heat-stable enterotoxin binds guanylyl cyclase C (GUCY2C) on intestinal
    epithelium and increases the receptor's guanylate-cyclase activity.
  role: molecular mechanism
  cell_types:
  - preferred_term: enterocyte of epithelium of small intestine
    term:
      id: CL:1000334
      label: enterocyte of epithelium of small intestine
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  molecular_functions:
  - preferred_term: guanylate cyclase activity
    modifier: INCREASED
    term:
      id: GO:0004383
      label: guanylate cyclase activity
  genes:
  - preferred_term: GUCY2C
    term:
      id: hgnc:4688
      label: GUCY2C
  downstream:
  - target: GUCY2C-dependent cGMP production
    causal_link_type: DIRECT
    description: Ligand-activated GUCY2C catalyzes formation of cGMP.
  evidence:
  - reference: PMID:11952098
    reference_title: Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Guanylyl cyclase C (GC-C) was found to function as the principal receptor
      for heat-stable enterotoxins (STa), major causative factors in E. coli-induced
      secretory diarrhea.
    explanation: Identifies GUCY2C as the principal epithelial receptor for E. coli heat-stable enterotoxin.
- name: Heat-labile enterotoxin activation of epithelial G protein-adenylyl cyclase
  description: >-
    ETEC heat-labile enterotoxin binds an intestinal epithelial receptor and
    delivers an enzymatic subunit that modifies the G protein coupled to
    adenylyl cyclase, increasing cyclase activity.
  role: molecular mechanism
  cell_types:
  - preferred_term: enterocyte of epithelium of small intestine
    term:
      id: CL:1000334
      label: enterocyte of epithelium of small intestine
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  molecular_functions:
  - preferred_term: adenylate cyclase activity
    modifier: INCREASED
    term:
      id: GO:0004016
      label: adenylate cyclase activity
  downstream:
  - target: Adenylyl-cyclase-dependent cAMP production
    causal_link_type: DIRECT
    description: Toxin-mediated G-protein modification stimulates adenylyl cyclase and cAMP production.
  evidence:
  - reference: PMID:1480112
    reference_title: Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Both toxins bind receptors in intestinal epithelial cells and insert an
      enzymatic subunit that modifies a G protein associated with the adenylate
      cyclase complex.
    explanation: Directly supports the receptor-to-G-protein/adenylyl-cyclase step for E. coli heat-labile toxin.
- name: GUCY2C-dependent cGMP production
  description: Activated epithelial GUCY2C increases intracellular cGMP, initiating the secretory signaling branch.
  role: molecular mechanism
  cell_types:
  - preferred_term: enterocyte of epithelium of small intestine
    term:
      id: CL:1000334
      label: enterocyte of epithelium of small intestine
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  biological_processes:
  - preferred_term: cGMP biosynthetic process
    modifier: INCREASED
    term:
      id: GO:0006182
      label: cGMP biosynthetic process
  genes:
  - preferred_term: GUCY2C
    term:
      id: hgnc:4688
      label: GUCY2C
  downstream:
  - target: CFTR-mediated epithelial chloride secretion
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cGMP-dependent protein kinase activation
    description: cGMP activates PKG, which promotes CFTR opening.
  - target: Inhibition of NHE3-mediated epithelial sodium absorption
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cGMP-dependent protein kinase activation
    description: cGMP/PKG signaling inhibits the apical sodium-hydrogen exchanger.
  evidence:
  - reference: PMID:27481254
    reference_title: Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Enteroid secretion depended on canonical molecular signaling events
      responsible for ETEC-induced diarrhea, including cyclic GMP (cGMP) produced
      by GUCY2C, activation of cGMP-dependent protein kinase (PKG), and opening of
      the cystic fibrosis transmembrane conductance regulator (CFTR).
    explanation: Human and mouse intestinal enteroids connect GUCY2C-derived cGMP to PKG and CFTR opening.
- name: Adenylyl-cyclase-dependent cAMP production
  description: Toxin-activated epithelial adenylyl cyclase increases intracellular cAMP and drives the secretory signaling branch.
  role: molecular mechanism
  cell_types:
  - preferred_term: enterocyte of epithelium of small intestine
    term:
      id: CL:1000334
      label: enterocyte of epithelium of small intestine
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  biological_processes:
  - preferred_term: cAMP biosynthetic process
    modifier: INCREASED
    term:
      id: GO:0006171
      label: cAMP biosynthetic process
  pathways:
  - preferred_term: cAMP/PKA signal transduction
    modifier: INCREASED
    term:
      id: GO:0141156
      label: cAMP/PKA signal transduction
  downstream:
  - target: CFTR-mediated epithelial chloride secretion
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - protein kinase A activation
    description: Increased cAMP activates PKA, which promotes CFTR-dependent chloride secretion.
  evidence:
  - reference: PMID:1480112
    reference_title: Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The consequent stimulated production of cyclic AMP, or other factors such
      as increased synthesis of prostaglandins by intoxicated cells, initiates a
      metabolic cascade that results in the excessive secretion of fluid and
      electrolytes characteristic of the disease.
    explanation: Connects heat-labile-toxin action to increased cAMP and the downstream secretory cascade.
- name: CFTR-mediated epithelial chloride secretion
  description: cGMP/PKG and cAMP/PKA signaling increase opening of apical CFTR channels and chloride secretion into the intestinal lumen.
  role: cellular mechanism
  cell_types:
  - preferred_term: enterocyte of epithelium of small intestine
    term:
      id: CL:1000334
      label: enterocyte of epithelium of small intestine
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  biological_processes:
  - preferred_term: chloride transmembrane transport
    modifier: INCREASED
    term:
      id: GO:1902476
      label: chloride transmembrane transport
  molecular_functions:
  - preferred_term: chloride channel activity
    modifier: INCREASED
    term:
      id: GO:0005254
      label: chloride channel activity
  genes:
  - preferred_term: CFTR
    term:
      id: hgnc:1884
      label: CFTR
  downstream:
  - target: Net intestinal electrolyte and water secretion
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - luminal osmotic water movement
    description: Luminal chloride secretion draws counterions and water into the intestinal lumen.
  evidence:
  - reference: PMID:27481254
    reference_title: Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Importantly, pharmacological inhibition of CFTR abrogated enteroid fluid
      secretion, providing proof of concept for the utility of this model to
      screen antidiarrheal agents.
    explanation: Shows that CFTR activity is required for enterotoxin-induced fluid secretion in intestinal enteroids.
- name: Inhibition of NHE3-mediated epithelial sodium absorption
  description: GUCY2C/cGMP signaling inhibits the apical sodium-hydrogen exchanger, decreasing epithelial sodium absorption.
  role: cellular mechanism
  cell_types:
  - preferred_term: enterocyte of epithelium of small intestine
    term:
      id: CL:1000334
      label: enterocyte of epithelium of small intestine
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  biological_processes:
  - preferred_term: sodium ion transmembrane transport
    modifier: DECREASED
    term:
      id: GO:0035725
      label: sodium ion transmembrane transport
  molecular_functions:
  - preferred_term: sodium:proton antiporter activity
    modifier: DECREASED
    term:
      id: GO:0015385
      label: sodium:proton antiporter activity
  genes:
  - preferred_term: SLC9A3
    term:
      id: hgnc:11073
      label: SLC9A3
  downstream:
  - target: Net intestinal electrolyte and water secretion
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced electroneutral sodium uptake
    - luminal osmotic water retention
    description: Reduced sodium absorption reinforces net luminal electrolyte and water accumulation.
  evidence:
  - reference: PMID:11952098
    reference_title: Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In the intestine, activation of GC-C results in a dual action: stimulation
      of Cl and HCO3 secretion, through the opening of apical CFTR Cl channels;
      and inhibition of Na absorption, through blockade of an apical Na/H
      exchanger.
    explanation: Directly supports reduced sodium absorption through blockade of an apical sodium-hydrogen exchanger.
- name: Net intestinal electrolyte and water secretion
  description: Increased anion secretion together with reduced sodium absorption produces net electrolyte and water accumulation in the intestinal lumen.
  role: tissue consequence
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  downstream:
  - target: Acute watery diarrhea
    causal_link_type: DIRECT
    description: Excess luminal fluid is passed as loose, watery stool.
  - target: Dehydration
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - stool fluid loss exceeding oral replacement
    - systemic volume depletion
    description: Sustained gastrointestinal water and electrolyte loss that exceeds replacement can deplete systemic volume and cause dehydration.
  evidence:
  - reference: PMID:1480112
    reference_title: Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The consequent stimulated production of cyclic AMP, or other factors such
      as increased synthesis of prostaglandins by intoxicated cells, initiates a
      metabolic cascade that results in the excessive secretion of fluid and
      electrolytes characteristic of the disease.
    explanation: Supports the final secretory output of the ETEC heat-labile-toxin branch.
- name: Shigella invasion of the colonic epithelium
  description: >-
    In the Shigella subset of traveler's diarrhea, organisms invade the colonic
    epithelium and deliver type III secretion-system effectors into host cells.
    This branch is pathogen-conditioned and is separate from the ETEC
    enterotoxin mechanism.
  role: pathogen-specific initiating mechanism
  cell_types:
  - preferred_term: colonocyte
    term:
      id: CL:1000347
      label: colonocyte
  locations:
  - preferred_term: colonic epithelium
    term:
      id: UBERON:0000397
      label: colonic epithelium
  downstream:
  - target: Cytokine-mediated colonic inflammation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - type III secretion-system effector delivery
    - epithelial innate immune signaling
    description: Invasion and injected bacterial effectors activate epithelial and innate immune signaling that elicits intense colonic inflammation.
  evidence:
  - reference: PMID:23318141
    reference_title: Tips and tricks about Shigella invasion of epithelial cells.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Shigella, the causative agent of bacillary dysentery, invades the colonic
      epithelium where it elicits an intense inflammation leading to tissular
      destruction.
    explanation: Supports Shigella invasion as the initiating event upstream of intense inflammation and tissue destruction.
- name: Cytokine-mediated colonic inflammation
  description: >-
    In Shigella-associated disease, epithelial invasion triggers a
    cytokine-mediated inflammatory response in the colon. This inflammation is
    separated from the downstream epithelial necrosis and ulceration that it
    promotes.
  role: inflammatory mechanism
  locations:
  - preferred_term: colonic mucosa
    term:
      id: UBERON:0000317
      label: colonic mucosa
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Colonic epithelial necrosis and mucosal ulceration
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - neutrophil and cytokine effector injury
    description: The intense inflammatory response causes epithelial necrosis, colitis, and mucosal ulceration through immune effector injury.
  - target: Fever
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - systemic pyrogenic cytokine signaling
    description: The inflammatory response can produce febrile diarrhea through systemic cytokine signaling.
  evidence:
  - reference: PMID:21413292
    reference_title: Shigella.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The pathogenic mechanism of shigellosis is complex, involving a possible
      enterotoxic and/or cytotoxic diarrheal prodrome, cytokine-mediated
      inflammation of the colon, and necrosis of the colonic epithelium.
    explanation: Supports cytokine-mediated colonic inflammation upstream of epithelial necrosis.
- name: Colonic epithelial necrosis and mucosal ulceration
  description: >-
    In severe Shigella-associated colitis, inflammatory and cytotoxic injury
    produces necrosis of the colonic epithelium and ulceration of the mucosa.
  role: tissue consequence
  cell_types:
  - preferred_term: colonocyte
    term:
      id: CL:1000347
      label: colonocyte
  locations:
  - preferred_term: colonic mucosa
    term:
      id: UBERON:0000317
      label: colonic mucosa
  downstream:
  - target: Bloody diarrhea
    causal_link_type: DIRECT
    description: Ulcerated colonic mucosa permits blood and mucus to enter dysenteric stool.
  evidence:
  - reference: PMID:21413292
    reference_title: Shigella.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The resulting colitis and ulceration of the mucosa result in bloody,
      mucoid stools, and/or febrile diarrhea.
    explanation: Directly connects colitis and mucosal ulceration to bloody stool.
- name: Protozoal infection associated with persistent traveler's diarrhea
  description: >-
    Intestinal protozoa are a pathogen-conditioned cause of protracted diarrhea
    during or after travel. This syndrome-level node does not assign one
    parasite-specific epithelial mechanism to Giardia, Cryptosporidium,
    Cyclospora, and other protozoa.
  role: pathogen-specific initiating mechanism
  downstream:
  - target: Persistent diarrhea
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Parasite-specific epithelial and host-response mechanisms are omitted because they differ across protozoal causes.
  evidence:
  - reference: PMID:11389503
    reference_title: Traveler's diarrhea due to intestinal protozoa.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Intestinal protozoa account for a minority of cases of acute traveler's diarrhea, but they are common pathogens in travelers who experience protracted diarrhea during or after travel.
    explanation: Directly establishes protozoal infection as a cause of protracted travel-associated diarrhea.
- name: DNA Gyrase and Topoisomerase IV (Fluoroquinolone Target)
  description: >-
    Susceptible bacterial causes of traveler's diarrhea depend on DNA gyrase and
    topoisomerase IV; fluoroquinolones trap their DNA-enzyme complexes and block
    bacterial DNA replication. This is a therapeutic vulnerability rather than
    a syndrome-wide causal mechanism.
  role: therapeutic_vulnerability
  conforms_to: "bacterial_dna_topoisomerase_inhibition#DNA Gyrase and Topoisomerase IV (Fluoroquinolone Target)"
  biological_processes:
  - preferred_term: DNA Topological Change
    term:
      id: GO:0006265
      label: DNA topological change
  evidence:
  - reference: PMID:27449972
    reference_title: "Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Quinolones dually target DNA gyrase and topoisomerase IV binding to specific domains and conformations so as to block DNA strand passage catalysis and stabilize DNA-enzyme complexes that block the DNA replication apparatus and generate double breaks in DNA that underlie their bactericidal activity.
    explanation: Defines the bacterial topoisomerase target and bactericidal mechanism of fluoroquinolones.
- name: Bacterial mRNA Translation by the Ribosome
  description: >-
    Bacterial ribosomal translation is the conserved molecular target of
    macrolides such as azithromycin. This node represents an antibiotic
    vulnerability of susceptible bacterial etiologies, not a mechanism of viral
    or protozoal disease.
  role: therapeutic_vulnerability
  conforms_to: "bacterial_protein_synthesis_inhibition#Bacterial mRNA Translation by the Ribosome"
  biological_processes:
  - preferred_term: translation
    term:
      id: GO:0006412
      label: translation
  evidence:
  - reference: PMID:24336183
    reference_title: Ribosome-targeting antibiotics and mechanisms of bacterial resistance.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The ribosome is one of the main antibiotic targets in the bacterial cell.
    explanation: Establishes the bacterial ribosome as a central antibiotic target.
- name: Bacterial RNA Polymerase (Rifamycin Target)
  description: >-
    Bacterial DNA-dependent RNA polymerase is the molecular target of rifamycins,
    including the nonabsorbed derivative rifaximin used for selected noninvasive
    E. coli disease.
  role: therapeutic_vulnerability
  conforms_to: "bacterial_rna_polymerase_inhibition#Bacterial RNA Polymerase (Rifamycin Target)"
  biological_processes:
  - preferred_term: DNA-templated transcription
    term:
      id: GO:0006351
      label: DNA-templated transcription
  evidence:
  - reference: PMID:32342856
    reference_title: Inhibition of RNA Polymerase by Rifampicin and Rifamycin-Like Molecules.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The most clinically important and extensively studied class of antibiotics known to inhibit bacterial RNAP are the rifamycins.
    explanation: Directly establishes bacterial RNA polymerase as the rifamycin target.
phenotypes:
- name: Acute watery diarrhea
  description: Acute loose or watery stools are the defining manifestation; this entry's mechanistic graph specifically models the ETEC secretory subset.
  phenotype_term:
    preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  evidence:
  - reference: PMID:39530798
    reference_title: "Etiology and Epidemiology of Travelers' Diarrhea among US Military and Adult Travelers, 2018-2023."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Symptoms can range from mild cramps and loose stool to bloody diarrhea, fever, abdominal pain, and vomiting.
    explanation: Supports loose stool as a core manifestation across the clinical spectrum.
- name: Abdominal cramps or pain
  description: Cramping or abdominal pain commonly accompanies the diarrheal illness.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:39530798
    reference_title: "Etiology and Epidemiology of Travelers' Diarrhea among US Military and Adult Travelers, 2018-2023."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Symptoms can range from mild cramps and loose stool to bloody diarrhea, fever, abdominal pain, and vomiting.
    explanation: Directly identifies cramps and abdominal pain in travelers with diarrhea.
- name: Nausea
  frequency: 38% (61/160) in a prospective traveler cohort
  description: Nausea commonly accompanies an acute episode and is associated with greater functional inconvenience.
  phenotype_term:
    preferred_term: Nausea
    term:
      id: HP:0002018
      label: Nausea
  evidence:
  - reference: PMID:22099542
    reference_title: "Inconvenience due to travelers' diarrhea: a prospective follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Nausea2 61 (38) 25 (23) 36 (68)
    explanation: The prospective cohort's Table 4 reports nausea in 61 of 160 affected travelers (38%).
- name: Bowel urgency
  frequency: 71% (114/160) in a prospective traveler cohort
  description: Fecal urgency is a common and functionally disruptive manifestation of acute traveler's diarrhea.
  phenotype_term:
    preferred_term: Bowel urgency
    term:
      id: HP:0012701
      label: Bowel urgency
  evidence:
  - reference: PMID:22099542
    reference_title: "Inconvenience due to travelers' diarrhea: a prospective follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Fecal urgency 1 114 (71) 69 (65) 45 (85)
    explanation: Directly reports fecal urgency in 71% of affected travelers.
- name: Vomiting
  description: Vomiting can accompany traveler's diarrhea and is particularly prominent with some viral causes.
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:39530798
    reference_title: "Etiology and Epidemiology of Travelers' Diarrhea among US Military and Adult Travelers, 2018-2023."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Symptoms can range from mild cramps and loose stool to bloody diarrhea, fever, abdominal pain, and vomiting.
    explanation: Directly identifies vomiting in the observed clinical spectrum.
- name: Fever
  description: Fever can accompany inflammatory or invasive pathogen-associated disease.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: PMID:39530798
    reference_title: "Etiology and Epidemiology of Travelers' Diarrhea among US Military and Adult Travelers, 2018-2023."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Symptoms can range from mild cramps and loose stool to bloody diarrhea, fever, abdominal pain, and vomiting.
    explanation: Directly identifies fever within the observed clinical spectrum.
- name: Bloody diarrhea
  description: Dysentery can occur with invasive bacterial causes and marks a clinically severe presentation.
  phenotype_term:
    preferred_term: Bloody diarrhea
    term:
      id: HP:0025085
      label: Bloody diarrhea
  evidence:
  - reference: PMID:39530798
    reference_title: "Etiology and Epidemiology of Travelers' Diarrhea among US Military and Adult Travelers, 2018-2023."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Symptoms can range from mild cramps and loose stool to bloody diarrhea, fever, abdominal pain, and vomiting.
    explanation: Directly identifies bloody diarrhea within the observed clinical spectrum.
- name: Dehydration
  description: Fluid loss can cause dehydration, the most common reported complication.
  phenotype_term:
    preferred_term: Dehydration
    term:
      id: HP:0001944
      label: Dehydration
  evidence:
  - reference: PMID:31084597
    reference_title: "Travelers' Diarrhea: A Clinical Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Dehydration is the most common complication.
    explanation: Directly supports dehydration as the principal complication.
- name: Persistent diarrhea
  description: >-
    Diarrhea lasting beyond the acute episode is particularly associated with
    protozoal infection, although postinfectious and unmasked chronic disorders
    can produce a similar persistent presentation.
  phenotype_term:
    preferred_term: Protracted diarrhea
    term:
      id: HP:0004385
      label: Protracted diarrhea
  evidence:
  - reference: PMID:11389503
    reference_title: Traveler's diarrhea due to intestinal protozoa.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Intestinal protozoa account for a minority of cases of acute traveler's diarrhea, but they are common pathogens in travelers who experience protracted diarrhea during or after travel.
    explanation: Supports protracted diarrhea as a clinically important protozoal presentation during or after travel.
- name: Post-infectious irritable bowel syndrome
  description: A subset of travelers has persistent or recurrent gastrointestinal symptoms compatible with PI-IBS after the acute infection resolves.
  phenotype_term:
    preferred_term: irritable bowel syndrome
    term:
      id: MONDO:0005052
      label: irritable bowel syndrome
  evidence:
  - reference: PMID:36881659
    reference_title: "Post-infectious irritable bowel syndrome following a diagnosis of traveller's diarrhoea: a comprehensive characterization of clinical and laboratory parameters."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified 669 travellers with a diagnosis of TD. Sixty-eight (10.2%)
      of these travellers, mean age 33 years and 36 (52.9%) women, developed
      PI-IBS.
    explanation: Quantifies PI-IBS in a retrospective referral-center cohort after traveler's diarrhea.
  review_notes: >-
    This sequela is intentionally not connected to the acute ETEC secretory
    graph because its pathogen-specific and host mechanisms remain unresolved.
environmental:
- name: Exposure to fecally contaminated water during travel
  description: Drinking or consuming water contaminated by feces exposes travelers to enteric pathogens.
  effect: Increases risk of pathogen ingestion and traveler's diarrhea.
  exposure_term:
    preferred_term: exposure to contaminated water
    term:
      id: ECTO:7000119
      label: exposure to contaminated water
  influences_mechanisms:
  - target: ETEC colonization-factor adhesion to small-intestinal enterocytes
    environmental_effect: TRIGGERS
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: When contaminated water carries viable ETEC, ingestion and passage to the small intestine precede epithelial adhesion.
    evidence:
    - reference: PMID:31084597
      reference_title: "Travelers' Diarrhea: A Clinical Review."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces.
      explanation: Establishes fecally contaminated water ingestion as an upstream acquisition route.
  - target: Shigella invasion of the colonic epithelium
    environmental_effect: TRIGGERS
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: When contaminated water carries viable Shigella, ingestion and gastrointestinal transit precede colonic epithelial invasion.
    evidence:
    - reference: PMID:21413292
      reference_title: Shigella.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Shigellosis also presents a significant risk to travelers from developed
        countries when visiting in endemic areas, and sporadic food or
        water-borne outbreaks occur in developed countries.
      explanation: Supports travel risk and food- or water-borne acquisition upstream of Shigella invasion.
  - target: Protozoal infection associated with persistent traveler's diarrhea
    environmental_effect: TRIGGERS
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: When contaminated water carries viable protozoa, ingestion and gastrointestinal transit precede intestinal infection.
    evidence:
    - reference: PMID:31084597
      reference_title: "Travelers' Diarrhea: A Clinical Review."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces.
      explanation: Establishes fecally contaminated water ingestion as an upstream acquisition route for the heterogeneous syndrome.
  evidence:
  - reference: PMID:31084597
    reference_title: "Travelers' Diarrhea: A Clinical Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces.
    explanation: Directly supports contaminated water as a traveler's diarrhea exposure.
- name: Exposure to fecally contaminated food during travel
  description: Eating food contaminated by feces exposes travelers to enteric pathogens.
  effect: Increases risk of pathogen ingestion and traveler's diarrhea.
  influences_mechanisms:
  - target: ETEC colonization-factor adhesion to small-intestinal enterocytes
    environmental_effect: TRIGGERS
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: When contaminated food carries viable ETEC, ingestion and passage to the small intestine precede epithelial adhesion.
    evidence:
    - reference: PMID:31084597
      reference_title: "Travelers' Diarrhea: A Clinical Review."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces.
      explanation: Establishes fecally contaminated food ingestion as an upstream acquisition route.
  - target: Shigella invasion of the colonic epithelium
    environmental_effect: TRIGGERS
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: When contaminated food carries viable Shigella, ingestion and gastrointestinal transit precede colonic epithelial invasion.
    evidence:
    - reference: PMID:21413292
      reference_title: Shigella.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Shigellosis also presents a significant risk to travelers from developed
        countries when visiting in endemic areas, and sporadic food or
        water-borne outbreaks occur in developed countries.
      explanation: Supports travel risk and food- or water-borne acquisition upstream of Shigella invasion.
  - target: Protozoal infection associated with persistent traveler's diarrhea
    environmental_effect: TRIGGERS
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: When contaminated food carries viable protozoa, ingestion and gastrointestinal transit precede intestinal infection.
    evidence:
    - reference: PMID:31084597
      reference_title: "Travelers' Diarrhea: A Clinical Review."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces.
      explanation: Establishes fecally contaminated food ingestion as an upstream acquisition route for the heterogeneous syndrome.
  evidence:
  - reference: PMID:31084597
    reference_title: "Travelers' Diarrhea: A Clinical Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces.
    explanation: Directly supports contaminated food as a traveler's diarrhea exposure.
  review_notes: >-
    No sufficiently specific current ECTO term for fecally contaminated food was
    found in the configured ontology, so this exposure remains unbound rather
    than being assigned an inaccurate broader term.
diagnosis:
- name: Selective pathogen testing in severe, dysenteric, or high-risk illness
  description: >-
    Pathogen-directed testing is most important for severe or bloody diarrhea
    and for patients at increased risk of a severe course; routine testing is
    not implied for every self-limited episode.
  diagnosis_term:
    preferred_term: Diagnostic Procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  evidence:
  - reference: PMID:39879968
    reference_title: "[Traveler's diarrhea]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Pathogen diagnostics are indicated for severe or dysenteric courses as well as for increased risk of severe courses.
    explanation: Directly supports severity- and risk-based selection for pathogen testing.
- name: Stool culture with organism-directed PCR, antigen, or microscopy testing
  description: >-
    Stool culture is central when pathogen identification is indicated and can
    be supplemented by PCR, antigen testing, or microscopy according to the
    suspected organism and illness duration.
  evidence:
  - reference: PMID:39879968
    reference_title: "[Traveler's diarrhea]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: A central component of pathogen diagnostics is stool culture. To detect specific pathogens, this is expanded to include stool microscopy, PCR, and antigen diagnostics.
    explanation: Establishes stool culture as the central diagnostic component and supports organism-directed microscopy, PCR, and antigen testing.
- name: Polymerase chain reaction testing of stool
  description: Molecular testing can detect pathogen nucleic acids when targeted or multiplex assays are clinically appropriate.
  diagnosis_term:
    preferred_term: Polymerase Chain Reaction
    term:
      id: NCIT:C17003
      label: Polymerase Chain Reaction
  evidence:
  - reference: PMID:39879968
    reference_title: "[Traveler's diarrhea]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: To detect specific pathogens, this is expanded to include stool microscopy, PCR, and antigen diagnostics.
    explanation: Supports PCR as a clinically directed pathogen-detection method rather than only as a surveillance assay.
- name: Culture-based antimicrobial susceptibility testing when possible
  description: >-
    Culture and susceptibility testing can guide therapy and preserve regional
    resistance surveillance, including after an initial culture-independent
    pathogen result.
  diagnosis_term:
    preferred_term: Diagnostic Procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  evidence:
  - reference: PMID:41591385
    reference_title: "GeoSentinel Analysis of Travelers' Diarrhea Antimicrobial Resistance Patterns."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Antimicrobial susceptibility from culture should be obtained when possible,
      including after pathogen detection by culture-independent methods.
    explanation: Directly supports culture-based susceptibility testing in the setting of geographically variable resistance.
- name: Blood culture and malaria evaluation for a febrile returning traveler
  description: >-
    Fever after travel broadens the evaluation beyond uncomplicated diarrhea;
    blood culture and exposure-directed malaria testing are important red-flag
    investigations.
  diagnosis_term:
    preferred_term: Diagnostic Procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  evidence:
  - reference: PMID:39879968
    reference_title: "[Traveler's diarrhea]."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: If there is a fever, a blood culture and, depending on exposure, malaria diagnosis should be carried out.
    explanation: Directly supports blood culture and exposure-dependent malaria evaluation in febrile illness after travel.
- name: Protozoal evaluation for persistent diarrhea
  description: >-
    Persistent or chronic diarrhea during or after travel warrants targeted
    examination for Giardia, Entamoeba, Cryptosporidium, Cyclospora, and other
    intestinal protozoa using organism-appropriate microscopy, antigen, or PCR
    methods.
  diagnosis_term:
    preferred_term: Diagnostic Procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  evidence:
  - reference: PMID:11389503
    reference_title: Traveler's diarrhea due to intestinal protozoa.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Evaluation of the traveler with chronic diarrhea should include a careful examination for typical infecting organisms, such as Giardia and Entamoeba species, as well as for emerging parasites, such as Cryptosporidium species, Cyclospora species, and microsporidia.
    explanation: Directly supports a broad protozoal work-up for chronic post-travel diarrhea.
differential_diagnoses:
- name: Post-infectious irritable bowel syndrome
  disease_term:
    preferred_term: irritable bowel syndrome
    term:
      id: MONDO:0005052
      label: irritable bowel syndrome
  description: >-
    Persistent gastrointestinal symptoms can continue after the acute infection
    has cleared and may represent PI-IBS rather than ongoing enteric infection.
  distinguishing_features:
  - Persistent symptoms after pathogen clearance favor a postinfectious process over active infection.
  evidence:
  - reference: PMID:21180583
    reference_title: Management of the returning traveler with diarrhea.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Postinfectious processes represent a second cause and comprise temporary lactose malabsorption and postinfectious irritable bowel syndrome, now considered a major cause of persistent TD.
    explanation: Establishes PI-IBS as a major noninfectious explanation for persistent symptoms after traveler's diarrhea.
- name: Inflammatory bowel disease unmasked after traveler's diarrhea
  disease_term:
    preferred_term: inflammatory bowel disease
    term:
      id: MONDO:0005265
      label: inflammatory bowel disease
  description: >-
    An incident chronic inflammatory bowel disorder can first become apparent
    after an acute travel-associated diarrheal episode and should not be assumed
    to represent persistent infection.
  distinguishing_features:
  - Evidence of chronic intestinal inflammation despite an unrevealing infectious work-up favors inflammatory bowel disease.
  evidence:
  - reference: PMID:21180583
    reference_title: Management of the returning traveler with diarrhea.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Finally, apparently unrelated chronic diseases causing diarrhea are occasionally unmasked by TD and represent a third type of persistent TD, among which the well established case of incident inflammatory bowel disease poses intriguing pathogenesis questions.
    explanation: Directly identifies incident inflammatory bowel disease as a chronic disorder that can be unmasked by traveler's diarrhea.
- name: Clostridioides difficile colitis after antimicrobial exposure
  disease_term:
    preferred_term: Clostridium difficile colitis
    term:
      id: MONDO:0000705
      label: Clostridium difficile colitis
  description: >-
    C. difficile colitis is an important alternative explanation for persistent
    or recurrent diarrhea after antibiotics taken during travel.
  distinguishing_features:
  - Recent antimicrobial exposure increases concern for C. difficile colitis.
  evidence:
  - reference: PMID:9658255
    reference_title: Persistent diarrhea in the returned traveler.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: If the patient is immunocompromised, microsporidia and Isospora become more likely, and a prior history of antimicrobial use raises the possibility of C. difficile colitis.
    explanation: Directly supports C. difficile colitis as an antibiotic-associated cause to consider in the returned traveler.
treatments:
- name: Supportive management without antibiotics for mild illness
  description: >-
    Mild traveler's diarrhea is managed with hydration and symptom-directed
    care; routine antibiotics are not recommended when illness is tolerable and
    does not interfere with planned activities.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:31084597
    reference_title: "Travelers' Diarrhea: A Clinical Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: For mild travelers' diarrhea, the use of antibiotic is not recommended.
    explanation: Directly supports antibiotic stewardship for mild illness.
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Tolerable, not distressing, does not interfere with planned activities
    explanation: Defines mild traveler's diarrhea by functional impact.
- name: Oral rehydration therapy
  description: Oral replacement of water and electrolytes is first-line supportive treatment; intravenous rehydration is reserved for severe dehydration or sepsis.
  treatment_term:
    preferred_term: fluid replacement therapy
    term:
      id: NCIT:C66896
      label: Hydration Therapy
  target_mechanisms:
  - target: Net intestinal electrolyte and water secretion
    treatment_effect: BYPASSES
    description: Rehydration replaces the water and electrolytes lost through ongoing intestinal secretion without requiring toxin-pathway inhibition.
    evidence:
    - reference: PMID:35839362
      reference_title: "Acute Diarrhea in Adults."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: In all cases, management begins with replacing water, electrolytes, and nutrients. Oral rehydration is preferred; however, signs of severe dehydration or sepsis warrant intravenous rehydration.
      explanation: Supports replacement therapy as a compensatory intervention for diarrheal fluid and electrolyte loss.
  evidence:
  - reference: PMID:35839362
    reference_title: "Acute Diarrhea in Adults."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: In all cases, management begins with replacing water, electrolytes, and nutrients. Oral rehydration is preferred; however, signs of severe dehydration or sepsis warrant intravenous rehydration.
    explanation: Supports oral rehydration as preferred initial management and identifies escalation conditions.
- name: Loperamide for mild illness
  description: >-
    Loperamide can provide symptom relief in mild traveler's diarrhea, but it
    should not be used as monotherapy when bloody diarrhea or fever suggests
    invasive or inflammatory disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: loperamide
      term:
        id: CHEBI:6532
        label: loperamide
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:28521004
    reference_title: "Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Strong evidence supports the effectiveness of antimicrobial therapy in
      most cases of moderate to severe travelers' diarrhea, while either
      increasing intake of fluids only or loperamide or bismuth subsalicylate
      may suffice for most cases of mild diarrhea.
    explanation: Graded guideline support for loperamide as an option in mild disease.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK620898/
    reference_title: "Travelers’ Diarrhea - CDC Yellow Book, 2026 edition - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Antimotility agents alone are not recommended for patients with bloody diarrhea or those who have diarrhea and fever.
    explanation: Establishes the red-flag limitation against loperamide monotherapy in dysenteric or febrile illness.
- name: Bismuth subsalicylate for mild illness or short-term prophylaxis
  description: >-
    Bismuth subsalicylate is a non-antibiotic option for symptom management in
    mild illness and can reduce short-term traveler's-diarrhea incidence by
    about 50%. Prophylactic use is limited by frequent dosing, lack of safety
    data beyond three weeks, and contraindications including aspirin allergy,
    gout, renal insufficiency, and interacting medicines.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bismuth subsalicylate
      term:
        id: CHEBI:261649
        label: bismuth subsalicylate
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:28521004
    reference_title: "Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Strong evidence supports the effectiveness of antimicrobial therapy in
      most cases of moderate to severe travelers' diarrhea, while either
      increasing intake of fluids only or loperamide or bismuth subsalicylate
      may suffice for most cases of mild diarrhea.
    explanation: Graded guideline support for bismuth subsalicylate as an option in mild disease.
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The primary agent studied for prevention of TD, other than antibiotics, is bismuth subsalicylate (BSS). Studies from Mexico have shown that this agent reduces the incidence of TD by approximately 50%.
    explanation: Establishes BSS as the principal studied non-antibiotic prophylactic and quantifies the reported incidence reduction.
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Travelers with aspirin allergy, gout, or renal insufficiency and those taking anticoagulants, methotrexate, or probenecid should not take BSS.
    explanation: States important contraindications for prophylactic or therapeutic BSS use.
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Studies have not established the safety of BSS use for &gt;3 weeks. Because of the number of tablets required and the inconvenient dosing, BSS is not commonly used as TD prophylaxis.
    explanation: Establishes the duration evidence gap and practical dosing limitation.
- name: Avoid routine antibiotic prophylaxis
  description: >-
    Prophylactic antibiotics are not recommended for most travelers because
    adverse effects, C. difficile infection, microbiome disruption, and
    acquisition or carriage of antimicrobial-resistant bacteria generally
    outweigh benefit. They may be considered rarely for short-term travelers
    who are high-risk hosts.
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK620898/
    reference_title: "Travelers’ Diarrhea - CDC Yellow Book, 2026 edition - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Prophylactic antibiotics are not recommended for most travelers.
    explanation: States the current default against routine antibiotic prophylaxis.
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: For almost all travelers, though, the risks associated with the use of prophylactic antibiotics, including side effects, <em>Clostridioides difficile</em> infection, and increased risk of carriage of antimicrobial-resistant bacteria, outweigh the potential benefits. Prophylactic antibiotics might rarely be considered for short-term travelers who are high-risk hosts (e.g., immunocompromised people or people who have significant medical comorbidities).
    explanation: Directly supports the adverse-effect, C. difficile, resistant-carriage, and rare high-risk-host qualifications.
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Prophylactic antibiotics afford no protection against nonbacterial pathogens and can remove normally protective microflora from the bowel, increasing the risk for acquisition of resistant bacterial pathogens.
    explanation: Directly supports the microbiome-disruption and resistant-pathogen acquisition rationale.
  - reference: PMID:28520998
    reference_title: "Medications for the prevention and treatment of travellers' diarrhea."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Prevention of TD with antibiotics has been recommended only under special circumstances.
    explanation: Supports reserving prophylaxis for exceptional circumstances rather than routine use.
  - reference: PMID:25613287
    reference_title: "Antimicrobials increase travelers' risk of colonization by extended-spectrum betalactamase-producing Enterobacteriaceae."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Eleven percent of those in subgroup TD-AB-, 21% in TD+AB-, and 37% in TD+AB+ acquired ESBL-PE. The risk proved to be highest in South Asia (46%); 23% became colonized in subgroup TD-AB-, 47% in TD+AB-, and 80% in TD+AB+.
    explanation: Quantifies the association between antibiotic-treated traveler's diarrhea and ESBL-producing Enterobacteriaceae acquisition.
- name: Targeted antiprotozoal therapy for giardiasis
  description: >-
    When Giardia is confirmed or strongly suspected as the cause of persistent
    traveler's diarrhea, organism-directed options include metronidazole,
    tinidazole, or nitazoxanide; this is not empiric treatment for every acute
    diarrheal episode.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: metronidazole
      term:
        id: CHEBI:6909
        label: metronidazole
    - preferred_term: tinidazole
      term:
        id: CHEBI:63627
        label: tinidazole
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Protozoal infection associated with persistent traveler's diarrhea
    treatment_effect: INHIBITS
    description: Organism-directed antiprotozoal therapy treats the ongoing Giardia infection represented by this pathogen-conditioned branch.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK620898/
      reference_title: "Travelers’ Diarrhea - CDC Yellow Book, 2026 edition - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The most common parasitic cause of TD is <i>Giardia duodenalis</i>, and treatment options include metronidazole, nitazoxanide, and tinidazole.
      explanation: Identifies Giardia as the main parasitic cause and lists organism-directed treatment options.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK620898/
    reference_title: "Travelers’ Diarrhea - CDC Yellow Book, 2026 edition - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The most common parasitic cause of TD is <i>Giardia duodenalis</i>, and treatment options include metronidazole, nitazoxanide, and tinidazole.
    explanation: Directly supports targeted treatment options for Giardia-associated traveler's diarrhea.
- name: Azithromycin for severe or dysenteric illness
  description: >-
    Azithromycin is an antibiotic option for moderate to severe disease and can
    be used for dysentery. Macrolides remain recommended for illness from South
    Central Asia and are preferred in sub-Saharan Africa because of high
    fluoroquinolone nonsusceptibility in Campylobacter; empiric therapy after
    South American exposure warrants closer monitoring because
    Shigella macrolide resistance and Campylobacter fluoroquinolone resistance
    pull selection in opposing directions.
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
    therapeutic_agent:
    - preferred_term: azithromycin
      term:
        id: CHEBI:2955
        label: azithromycin
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Bacterial mRNA Translation by the Ribosome
    treatment_effect: INHIBITS
    description: Azithromycin binds the bacterial 50S ribosomal subunit and inhibits bacterial protein synthesis in susceptible enteropathogens.
    evidence:
    - reference: PMID:18192791
      reference_title: Azithromycin resistance in Treponema pallidum.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: This mutation confers resistance by precluding macrolide binding to the bacterial 50S ribosomal subunit, of which 23S rRNA is a structural component.
      explanation: Establishes the conserved bacterial 50S ribosomal binding target of macrolides.
  evidence:
  - reference: PMID:31084597
    reference_title: "Travelers' Diarrhea: A Clinical Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Azithromycin can be used even for the treatment of dysentery whereas fluoroquinolones and rifaximin cannot be used for such purpose.
    explanation: Directly distinguishes azithromycin as an option for dysenteric disease.
  - reference: PMID:31084597
    reference_title: "Travelers' Diarrhea: A Clinical Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: For moderate travelers' diarrhea, antibiotics such as fluoroquinolones, azithromycin, and rifaximin may be used.
    explanation: Directly supports azithromycin as an antibiotic option for functionally moderate illness.
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Antibiotic treatment is advised (single-dose regimens may be used):
      <ul> <li>Azithromycin is preferred</li>
    explanation: The current functional-severity table identifies azithromycin as the preferred antibiotic for severe illness.
  - reference: PMID:41591385
    reference_title: "GeoSentinel Analysis of Travelers' Diarrhea Antimicrobial Resistance Patterns."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this cross-sectional study of travelers' diarrhea antimicrobial
      resistance patterns, there was marked variability of nonsusceptibility to
      2 major classes of antibiotics commonly used for treating travelers'
      diarrhea among global regions.
    explanation: Supports conditioning empiric macrolide selection on destination-specific resistance patterns.
  - reference: PMID:41591385
    reference_title: "GeoSentinel Analysis of Travelers' Diarrhea Antimicrobial Resistance Patterns."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although there is limited evidence associating in vitro AST results with
      treatment outcomes for acute diarrhea,29 given the high nonsusceptibility
      rates for fluoroquinolones in Campylobacter and Shigella species, it is
      reasonable to continue to recommend macrolides for TD originating or
      occurring in South Central Asia. Similarly, in sub-Saharan Africa, where
      Campylobacter infections were a common cause of TD, macrolides are
      preferred given that 60% of isolates were nonsusceptible to
      fluoroquinolones. In South America, where there is 78%
      nonsusceptibility to macrolides in Shigella species, as well as 71%
      nonsusceptibility to fluoroquinolones in Campylobacter species, patients
      receiving empiric therapy may need closer monitoring for persistent or
      worsening symptoms and possible broader antibiotic coverage.
    explanation: Directly provides region-conditioned empiric macrolide guidance and the South American monitoring caveat.
- name: Rifaximin for noninvasive Escherichia coli illness
  description: >-
    Rifaximin is a nonabsorbed antibiotic option for functionally moderate or
    severe, non-dysenteric illness only when noninvasive E. coli is the likely
    cause. It is not indicated for mild illness and is not appropriate for
    invasive or dysenteric disease.
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
    therapeutic_agent:
    - preferred_term: rifaximin
      term:
        id: CHEBI:75246
        label: rifaximin
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Bacterial RNA Polymerase (Rifamycin Target)
    treatment_effect: INHIBITS
    description: Rifaximin is a rifamycin derivative that inhibits bacterial RNA polymerase in susceptible noninvasive E. coli.
    evidence:
    - reference: PMID:32342856
      reference_title: Inhibition of RNA Polymerase by Rifampicin and Rifamycin-Like Molecules.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The most clinically important and extensively studied class of antibiotics known to inhibit bacterial RNAP are the rifamycins.
      explanation: Directly supports bacterial RNA polymerase as the target of the rifamycin class.
  evidence:
  - reference: PMID:32966000
    reference_title: Rifaximin.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Rifaximin is an antibiotic used to treat irritable bowel syndrome with diarrhea, reduce the risk of overt hepatic encephalopathy recurrence in adults, and treat travelers’ diarrhea caused by noninvasive strains of Escherichia coli.
    explanation: Supports the narrow organism/invasiveness indication for rifaximin.
  - reference: PMID:31084597
    reference_title: "Travelers' Diarrhea: A Clinical Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Azithromycin can be used even for the treatment of dysentery whereas fluoroquinolones and rifaximin cannot be used for such purpose.
    explanation: Supports exclusion of rifaximin from dysenteric illness.
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Rifaximin (for moderate, noninvasive diarrhea)
    explanation: Directly supports rifaximin for functionally moderate, noninvasive illness.
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Fluoroquinolones or rifaximin can be used for severe, non-dysenteric diarrhea
    explanation: Directly supports rifaximin as a conditional option for severe, non-dysenteric illness.
- name: Rifamycin SV for noninvasive Escherichia coli illness in adults
  description: >-
    Rifamycin SV is a nonabsorbed, enteric-coated antibiotic option for selected
    adults with non-dysenteric traveler's diarrhea caused by noninvasive E.
    coli. Travelers need clinical evaluation or a separate backup agent if
    invasive illness develops.
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
    therapeutic_agent:
    - preferred_term: rifamycin SV
      term:
        id: CHEBI:29673
        label: rifamycin SV
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Bacterial RNA Polymerase (Rifamycin Target)
    treatment_effect: INHIBITS
    description: Rifamycin SV inhibits bacterial RNA polymerase in susceptible noninvasive E. coli.
    evidence:
    - reference: PMID:32342856
      reference_title: Inhibition of RNA Polymerase by Rifampicin and Rifamycin-Like Molecules.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The most clinically important and extensively studied class of antibiotics known to inhibit bacterial RNAP are the rifamycins.
      explanation: Establishes bacterial RNA polymerase as the conserved rifamycin-class target.
  evidence:
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Another therapeutic option is rifamycin, approved to treat TD caused by noninvasive strains of <em>E. coli</em> in adults.
    explanation: Establishes the adult, noninvasive-E. coli indication.
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Two randomized clinical trials showed that rifamycin SV was superior to placebo and noninferior to ciprofloxacin in the treatment of TD.
    explanation: Summarizes the randomized trial evidence supporting rifamycin SV efficacy.
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: As with rifaximin, travelers taking rifamycin would need to seek medical care or carry a separate antibiotic (e.g., azithromycin) in case of infection due to an invasive pathogen.
    explanation: Establishes the invasive-disease limitation and backup-treatment requirement.
- name: Fluoroquinolone therapy in selected non-dysenteric cases
  description: >-
    A fluoroquinolone such as ciprofloxacin can be considered for selected
    moderate or severe non-dysenteric illness, but high and geographically
    variable nonsusceptibility substantially constrains empiric use.
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
    therapeutic_agent:
    - preferred_term: ciprofloxacin
      term:
        id: CHEBI:100241
        label: ciprofloxacin
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: DNA Gyrase and Topoisomerase IV (Fluoroquinolone Target)
    treatment_effect: INHIBITS
    description: Fluoroquinolones inhibit bacterial DNA gyrase and topoisomerase IV in susceptible enteropathogens.
    evidence:
    - reference: PMID:27449972
      reference_title: "Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Quinolones dually target DNA gyrase and topoisomerase IV binding to specific domains and conformations so as to block DNA strand passage catalysis and stabilize DNA-enzyme complexes that block the DNA replication apparatus and generate double breaks in DNA that underlie their bactericidal activity.
      explanation: Directly supports inhibition of the bacterial type II topoisomerase target.
  evidence:
  - reference: PMID:31084597
    reference_title: "Travelers' Diarrhea: A Clinical Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: For moderate travelers' diarrhea, antibiotics such as fluoroquinolones, azithromycin, and rifaximin may be used.
    explanation: Supports fluoroquinolones as a conditional option for moderate illness.
  - reference: url:https://www.cdc.gov/yellow-book/hcp/preparing-international-travelers/travelers-diarrhea.html
    reference_title: Travelers' Diarrhea | CDC Yellow Book
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Fluoroquinolones or rifaximin can be used for severe, non-dysenteric diarrhea
    explanation: Directly supports fluoroquinolones as a conditional option for severe, non-dysenteric illness.
  - reference: PMID:41591385
    reference_title: "GeoSentinel Analysis of Travelers' Diarrhea Antimicrobial Resistance Patterns."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among Campylobacter isolates, nonsusceptibility to fluoroquinolones was
      found in 206 of 274 isolates (75%; 95% CI, 70%-80%), and
      nonsusceptibility to macrolides was found in 30 of 255 isolates (12%; 95%
      CI, 8%-16%) and was highest in travelers to South Central Asia (45 of 51
      isolates; 88%; 95% CI, 76%-96%).
    explanation: Quantifies the resistance constraint that limits empiric fluoroquinolone use, especially for Campylobacter.
experimental_models:
- name: Human and mouse intestinal enteroid ST-secretion model
  description: >-
    Three-dimensional ex vivo intestinal enteroids derived from mouse and human
    epithelium express the GUCY2C secretory axis. Heat-stable ETEC enterotoxin
    produces quantifiable luminal fluid accumulation through
    GUCY2C-cGMP-PKG-CFTR signaling, and pharmacologic CFTR inhibition abrogates
    secretion.
  experimental_model_type: ORGANOID
  cell_source: Human and mouse intestinal epithelium
  culture_system: Three-dimensional ex vivo intestinal enteroids with luminal fluid-accumulation imaging
  conditions:
  - heat-stable ETEC enterotoxin challenge
  - linaclotide secretagogue challenge
  - pharmacologic CFTR inhibition
  publication: PMID:27481254
  modeled_mechanisms:
  - target: GUCY2C-dependent cGMP production
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      The enteroids retain the canonical GUCY2C-to-cGMP-to-PKG signaling axis
      needed for heat-stable-enterotoxin secretion.
    limitations: >-
      This is an ex vivo toxin-challenge system rather than intact pathogen
      infection and does not reproduce immune, microbiota, vascular, systemic,
      or travel-exposure compartments; it combines observations from two
      species.
    evidence:
    - reference: PMID:27481254
      reference_title: Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Enteroid secretion depended on canonical molecular signaling events responsible for ETEC-induced diarrhea, including cyclic GMP (cGMP) produced by GUCY2C, activation of cGMP-dependent protein kinase (PKG), and opening of the cystic fibrosis transmembrane conductance regulator (CFTR).
      explanation: Connects the model directly to the GUCY2C-cGMP-PKG secretory branch.
  - target: Net intestinal electrolyte and water secretion
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Heat-stable enterotoxin produces quantifiable fluid accumulation within
      enteroid lumens, recapitulating the net secretory output of ETEC disease.
    limitations: >-
      Luminal volume is a tissue-level epithelial secretion readout in an ex
      vivo toxin challenge; it does not model whole-organism stool output,
      hydration status, immune responses, microbiota, or intact infection.
    readouts:
    - name: Enteroid luminal fluid accumulation after heat-stable enterotoxin
      target: Net intestinal electrolyte and water secretion
      direction: INCREASED
      interpretation: Increased enteroid-lumen volume is the functional readout of toxin-induced epithelial secretion.
      evidence:
      - reference: PMID:27481254
        reference_title: Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: ST and its structural analog, linaclotide, an FDA-approved oral secretagog, induced fluid accumulation quantified simultaneously in scores of enteroid lumens, recapitulating ETEC-induced intestinal secretion.
        explanation: Directly defines the model's quantitative luminal-fluid readout.
    evidence:
    - reference: PMID:27481254
      reference_title: Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: ST and its structural analog, linaclotide, an FDA-approved oral secretagog, induced fluid accumulation quantified simultaneously in scores of enteroid lumens, recapitulating ETEC-induced intestinal secretion.
      explanation: Directly supports the model's tissue-level secretory output.
  - target: CFTR-mediated epithelial chloride secretion
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      CFTR opening is required for the enteroid secretory response, and
      pharmacologic CFTR inhibition rescues the fluid-accumulation readout.
    limitations: >-
      CFTR inhibition demonstrates pathway dependence in an epithelial ex vivo
      model but does not establish safety or efficacy of an antidiarrheal therapy
      in travelers.
    readouts:
    - name: Abrogation of enterotoxin-induced fluid secretion by CFTR inhibition
      target: CFTR-mediated epithelial chloride secretion
      direction: ABOLISHED
      interpretation: Loss of luminal fluid accumulation after CFTR inhibition shows that the modeled secretory output depends on CFTR.
      evidence:
      - reference: PMID:27481254
        reference_title: Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: Importantly, pharmacological inhibition of CFTR abrogated enteroid fluid secretion, providing proof of concept for the utility of this model to screen antidiarrheal agents.
        explanation: Directly reports rescue of the fluid-secretion phenotype by CFTR inhibition.
    evidence:
    - reference: PMID:27481254
      reference_title: Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Importantly, pharmacological inhibition of CFTR abrogated enteroid fluid secretion, providing proof of concept for the utility of this model to screen antidiarrheal agents.
      explanation: Establishes CFTR dependence and the model's experimental rescue response.
  evidence:
  - reference: PMID:27481254
    reference_title: Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Here, we reveal that mouse and human intestinal enteroids in three-dimensional ex vivo cultures express the components of the GUCY2C secretory signaling axis.
    explanation: Directly establishes the species, culture system, and modeled signaling-axis components.
datasets:
- accession: geo:GSE276378
  title: The MAIT cell response to controlled oral enterotoxigenic E. coli challenge
  description: >-
    Mucosa-associated invariant T (MAIT) cells recognize conserved microbial
    antigens presented by MR1 and contribute to barrier immunity. This human
    controlled ETEC challenge dataset profiles blood responses, with activation
    and proliferation most evident among participants who developed mild to
    severe diarrhea.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 28
  publication: PMID:40713903
  notes: >-
    Accession, title, sample count, organism, and direct ETEC challenge relevance
    were verified against GEO metadata. The previous aEPEC epithelial-cell
    dataset was removed because it was not a traveler's-diarrhea cohort or ETEC
    model.
discussions:
- discussion_id: gap_td_pathogen_and_resistance_stratification
  prompt: >-
    How should rapid pathogen identification and destination-specific
    antimicrobial-resistance surveillance be combined to select self-treatment
    or clinician-directed therapy for heterogeneous traveler's diarrhea?
  kind: KNOWLEDGE_GAP
  status: OPEN
  rationale: >-
    Molecular testing increasingly detects viral disease and mixed infections,
    bacterial rankings differ by method and geography, and susceptibility to
    fluoroquinolones and macrolides varies markedly across destinations. A
    universal ETEC-centered or single-antibiotic treatment rule is therefore
    not supported.
  evidence:
  - reference: PMID:41591385
    reference_title: "GeoSentinel Analysis of Travelers' Diarrhea Antimicrobial Resistance Patterns."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this cross-sectional study of travelers' diarrhea antimicrobial
      resistance patterns, there was marked variability of nonsusceptibility to
      2 major classes of antibiotics commonly used for treating travelers'
      diarrhea among global regions.
    explanation: Directly establishes regional variation in susceptibility to the major empiric antibiotic classes.
  - reference: PMID:40699254
    reference_title: "Travellers' diarrhoea - solidifying our knowledgebase."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Viral travellers' diarrhoea is more frequently recognised due to the improved sensitivity of molecular diagnostics.
    explanation: Supports the diagnostic-method dependence of observed etiology.
- discussion_id: gap_td_postinfectious_ibs_mechanism
  prompt: >-
    Which pathogen-specific, microbiome, epithelial, and host-response mechanisms
    determine who develops persistent postinfectious irritable bowel syndrome
    after traveler's diarrhea?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Post-infectious irritable bowel syndrome
  rationale: >-
    PI-IBS is a clinically documented sequela, but the available cohort evidence
    identifies associations rather than a causal mechanism that can honestly be
    joined to the acute ETEC secretory graph.
  evidence:
  - reference: PMID:36881659
    reference_title: "Post-infectious irritable bowel syndrome following a diagnosis of traveller's diarrhoea: a comprehensive characterization of clinical and laboratory parameters."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Parasitic infections, mainly giardiasis, seem to be associated with PI-IBS.
    explanation: Identifies a pathogen-class association without resolving the downstream mechanism.
  - reference: PMID:40699254
    reference_title: "Travellers' diarrhoea - solidifying our knowledgebase."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Better pathophysiological understanding and new intervention strategies are required to help alleviate the suffering of post-travellers' diarrhoea IBS.
    explanation: Explicitly identifies the unresolved post-travel PI-IBS pathophysiology as a research priority.
- discussion_id: hypothesis_td_enteral_magnesium_casr_translation
  prompt: >-
    Can enteral magnesium activation of epithelial CaSR safely reduce
    cyclic-nucleotide-mediated secretion in human ETEC traveler's diarrhea?
  kind: EMERGING_HYPOTHESIS
  status: OPEN
  attaches_to:
  - pathophysiology#CFTR-mediated epithelial chloride secretion
  - pathophysiology#Net intestinal electrolyte and water secretion
  rationale: >-
    Magnesium suppressed heat-stable-enterotoxin-induced chloride secretion in
    human T84 cells and reduced toxin-driven fluid accumulation in mouse models,
    but this remains preclinical evidence from epithelial and animal systems.
    It is not an established treatment for traveler's diarrhea, and human dose,
    safety, efficacy, and the risk of osmotic diarrhea remain unresolved.
  evidence:
  - reference: DOI:10.1172/jci171249
    reference_title: Mg2+ supplementation treats secretory diarrhea in mice by activating calcium-sensing receptor in intestinal epithelial cells
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Mg2+ (10 mM) also suppressed Cl- secretion induced by cholera toxin, heat-stable E. coli enterotoxin, and vasoactive intestinal peptide by 50%.
    explanation: Provides direct preclinical evidence that magnesium suppresses heat-stable-enterotoxin-induced secretion in an epithelial model.
  - reference: DOI:10.1172/jci171249
    reference_title: Mg2+ supplementation treats secretory diarrhea in mice by activating calcium-sensing receptor in intestinal epithelial cells
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In mouse intestinal closed loops, luminal Mg2+ treatment (20 mM) inhibited cholera toxin–induced fluid accumulation by 40%.
    explanation: Provides complementary in vivo mouse evidence for reduced toxin-driven intestinal fluid accumulation.
review_notes: >-
  MONDO has no configured exact term for traveler's diarrhea, so the disease is
  represented formally as a skos:closeMatch to MONDO:0001673 (diarrheal disease),
  with the travel context retained explicitly rather than implying an exact
  identity. The infectious-agent list represents well-supported etiologic
  breadth, whereas the causal pathograph deliberately models exemplar ETEC
  secretory, Shigella invasive-inflammatory, and persistent protozoal branches;
  none should be generalized to every bacterial, viral, or protozoal cause.
  Recent molecular surveillance does not support describing ETEC as universally
  the most common cause. Campylobacter and Giardia are etiologies, not
  differential diagnoses. GeneReviews review is not applicable to this acquired,
  etiologically heterogeneous infectious syndrome; host GUCY2C, CFTR, and
  SLC9A3 annotations are mechanistic targets, not germline causal claims. The
  retained GEO dataset is a direct human ETEC challenge study; the removed aEPEC
  cell-line dataset was a pathogen-relative model without direct
  traveler's-diarrhea relevance. Probiotic prophylaxis is not represented as a
  standard, and antibiotic prophylaxis is explicitly limited to rare special
  circumstances because routine use is discouraged.
  Organism-directed persistent-protozoal treatment is structured here for
  Giardia because it is the main parasitic cause of traveler's diarrhea; this
  does not imply that the Giardia regimen applies to amebiasis,
  cryptosporidiosis, or cyclosporiasis, whose distinct regimens are not modeled
  without corresponding organism-specific pathograph branches.
📚

References & Deep Research

Deep Research

2
Disorder ▸

Disorder

  • Name: Traveler's Diarrhea
  • Category: Infectious
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 28

Key Pathophysiology Nodes

  • Ingestion of contaminated food or water during travel
  • ETEC adherence via colonization factors
  • Enterotoxin-driven secretory diarrhea
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1016/j.heliyon.2024.e33038
  • DOI:10.1099/jmm.0.002097
  • DOI:10.1152/ajpgi.2001.281.2.g303
  • DOI:10.1172/jci171249
  • DOI:10.3389/fimmu.2023.1120331
  • DOI:10.5005/jp-journals-11002-0056
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 18 citations 2025-12-18T14:14:30.562290

Disease Pathophysiology Research Report

Target Disease - Disease Name: Traveler’s Diarrhea (TD) - MONDO ID: not specified in MONDO (as of current sources) - Category: Infectious

Executive Summary Traveler’s diarrhea arises predominantly from enterotoxigenic and enteropathogenic mechanisms that disrupt epithelial ion transport and barrier integrity, alongside inflammatory and enteric nervous system–mediated secretory reflexes. The core molecular pathways include cAMP- and cGMP-driven activation of CFTR chloride secretion, inhibition of apical Na+ absorption via NHE3 and DRA, tight-junction dysregulation by type III secretion system effectors, and Ca2+-dependent secretory signaling for certain viral etiologies. Recent work (2023–2024) highlights: (1) precise transporter-level derangements in EPEC, including NHE3, DRA/SLC26A3, SGLT1, MCT1 and SERT dysregulation; (2) ETEC STa/LT signaling into GC-C/cGMP and adenylate cyclase/cAMP converging on CFTR with NHE3 inhibition; (3) EAEC as a frequent TD etiology with high AMR carriage among travelers; and (4) a translational, mechanistically targeted antisecretory strategy—luminal Mg2+ activation of CaSR—to blunt cyclic nucleotide–mediated secretion in cell and mouse models (JCI 2024). (kaur2023pathophysiologyofenteropathogenic pages 11-12, kaur2023pathophysiologyofenteropathogenic pages 21-25, ye2024baicalinaluminumcomplexon pages 4-9, poh2025microbiologyandepidemiology pages 10-12, goncalves2024mg2+supplementationtreats pages 1-2, goncalves2024mg2+supplementationtreats pages 8-10)

Core Pathophysiology - Secretory diarrhea via cyclic nucleotides: ETEC heat-labile toxin (LT) activates adenylate cyclase → cAMP/PKA → CFTR phosphorylation, while heat-stable toxin (STa) activates GC-C (GUCY2C) → cGMP/PKG with cross-activation of PKA, stimulating CFTR and inhibiting NHE3, producing net Cl− secretion and impaired Na+ absorption. In vitro, ETEC increases cellular cAMP/cGMP, upregulates CFTR mRNA, and inhibits NHEs; a 2024 epithelial study confirmed STa→GUCY2C→cGMP/PKG and LT→cAMP/PKA cascades converging on CFTR/NHE3 dysfunction. (URL: https://doi.org/10.1016/j.heliyon.2024.e33038, Jun 2024) (ye2024baicalinaluminumcomplexon pages 4-9) - Tight-junction and transporter disruption (EPEC): EPEC T3SS effectors (EspF, Map, Tir, EspG, NleA) drive attaching-and-effacing lesions, microvillus effacement, tight-junction internalization (claudins, ZO-1/ZO-2), mitochondrial injury, and actin remodeling via N-WASP/Arp2/3. EPEC specifically inhibits NHE3 (SLC9A3), reduces apical DRA/SLC26A3 via EspG-dependent microtubule effects, suppresses SGLT1, and downregulates MCT1 and ASBT; SERT inhibition (via SHP2-mediated dephosphorylation) raises luminal 5-HT contributing to secretion. These changes impair electroneutral NaCl absorption and promote fluid loss. (URL: https://doi.org/10.5005/jp-journals-11002-0056, Apr 2023) (kaur2023pathophysiologyofenteropathogenic pages 11-12, kaur2023pathophysiologyofenteropathogenic pages 21-25) - Inflammatory/ENS amplification: Innate activation (e.g., IL-8, NF-κB) recruits neutrophils; neutrophil-derived AMP is converted luminally to adenosine, a potent secretagogue that drives CFTR-dependent Cl− secretion. ENS secretomotor reflexes involving VIP, cholinergic transmitters, 5-HT, PGE2, and NO can sustain secretion in later phases of infection. (URL: https://doi.org/10.1152/ajpgi.2001.281.2.g303, Aug 2001) (morris2001viii.pathologicalconsequences pages 5-7) - Viral mechanisms: Rotavirus NSP4 mobilizes intracellular Ca2+ and triggers early CFTR-independent secretion, with later ENS-mediated, cyclic nucleotide–dependent components; norovirus can drive ENS-linked secretory responses. (URL: https://doi.org/10.1152/ajpgi.2001.281.2.g303, Aug 2001) (morris2001viii.pathologicalconsequences pages 5-7) - CEACAM interactions: Pathogenic E. coli adhesins (Afa/Dr family; FimH/type 1 pili) engage CEACAMs (notably CEACAM6), enhancing mucosal adherence; cyclic nucleotide signaling downstream of ETEC toxins converges on CFTR/NHE3 pathology. (URL: https://doi.org/10.3389/fimmu.2023.1120331, Feb 2023) (sheikh2023interactionsofpathogenic pages 2-3)

Recent Developments (2023–2024 highlights) - EPEC transporter and barrier biology refined: 2023 review details inhibition of NHE3 and DRA, reduced SGLT1, MCT1, ASBT, and SERT dysregulation via SHP2, linking effector–host interactions to specific transporter defects and barrier loss. (Apr 2023) (kaur2023pathophysiologyofenteropathogenic pages 11-12, kaur2023pathophysiologyofenteropathogenic pages 21-25) - ETEC signaling consolidated in epithelial models: 2024 experiments demonstrate STa (cGMP/PKG) and LT (cAMP/PKA) synergistically activate CFTR and inhibit NHE3; PKC/CaMKII and Ca2+-activated Cl− channels implicated for STb. (Jun 2024) (ye2024baicalinaluminumcomplexon pages 4-9) - Mg2+-CaSR antisecretory strategy: 2024 JCI study shows luminal Mg2+ (10 mM) activates epithelial CaSR/Gq to drive PDE-mediated cAMP hydrolysis, suppressing CFTR Cl− secretion by ~65% in human T84 cells and ~50% against cholera toxin and ETEC ST, with in vivo efficacy (20 mM luminal Mg2+ reduced cholera toxin–induced fluid accumulation by ~40%; 10 mM converted net secretion to absorption in perfused mouse intestine). “Extracellular Mg2+…suppressed forskolin-induced Cl− secretion…by 65% at physiological levels…; Mg2+…also suppressed Cl− secretion induced by cholera toxin, heat-stable E. coli enterotoxin…by 50%…luminal Mg2+…inhibited cholera toxin–induced fluid accumulation by 40%…reversed net fluid transport from secretion to absorption.” (URL: https://doi.org/10.1172/jci171249, Jan 2024) (goncalves2024mg2+supplementationtreats pages 1-2, goncalves2024mg2+supplementationtreats pages 10-11, goncalves2024mg2+supplementationtreats pages 8-10, goncalves2024mg2+supplementationtreats pages 2-5) - EAEC in travelers and AMR: Enhanced UK surveillance (2016–2023) shows EAEC diagnoses rose fivefold (93→524/year), with 1,402 notifications; 79% of cases with travel history had foreign travel within 7 days. AMR detected in 73.5% of isolates; common resistance to fluoroquinolones (57.8%) and β-lactams (57.6%); hybrid STEC/EAEC strains are a concern. (URL: https://doi.org/10.1099/jmm.0.002097, Nov 2025) (poh2025microbiologyandepidemiology pages 10-12)

Current Applications and Implementations - Pathway-targeted therapies: The Mg2+-CaSR approach offers a mechanistically targeted, orally deliverable adjunct or modification to ORS for cyclic nucleotide–mediated secretory diarrheas (e.g., cholera, ETEC TD). Inclusion of ~10 mM Mg2+ in ORS suppressed CFTR-mediated secretion in perfused mouse intestine, with CaSR dependence demonstrated in epithelial-specific Casr knockout mice. (Jan 2024) (goncalves2024mg2+supplementationtreats pages 1-2, goncalves2024mg2+supplementationtreats pages 8-10) - Supportive care optimization: Recognition that EPEC/ETEC impair Na+-coupled absorption (NHE3, SGLT1) and DRA underscores the rationale for glucose–electrolyte ORS and suggests potential benefit from butyrate/SCFA and bile acid transport modulation where appropriate. (Apr 2023; Jun 2024) (kaur2023pathophysiologyofenteropathogenic pages 11-12, ye2024baicalinaluminumcomplexon pages 4-9) - Diagnostics/surveillance: Molecular panels detect EAEC/EPEC; surveillance highlights EAEC burden in travelers and high AMR, informing empiric therapy (e.g., azithromycin) and travel health guidance. (Nov 2025) (poh2025microbiologyandepidemiology pages 10-12)

Expert Opinions and Authoritative Analyses - Mechanistic consolidation in EPEC pathogenesis emphasizes coordinated T3SS effector action targeting transport and barrier proteins, explaining malabsorptive and secretory components; this frames transporter-restorative and barrier-protective interventions as rational targets. (Apr 2023) (kaur2023pathophysiologyofenteropathogenic pages 11-12, kaur2023pathophysiologyofenteropathogenic pages 21-25) - Translational antisecretory strategy: The 2024 JCI group positions CaSR as a central epithelial “brake” on cyclic nucleotide–driven secretion; Mg2+ appears to be the key physiological CaSR agonist at stool concentrations, providing a feasible, low-cost approach to mitigate CFTR-mediated fluid loss in TD. (Jan 2024) (goncalves2024mg2+supplementationtreats pages 1-2, goncalves2024mg2+supplementationtreats pages 2-5) - EAEC epidemiology/AMR: National surveillance authors recommend adding EAEC to diagnostic algorithms given disease burden, traveler association, and high AMR prevalence, and warn about hybrid STEC/EAEC risk. (Nov 2025) (poh2025microbiologyandepidemiology pages 10-12)

Relevant Statistics and Data - Mg2+-CaSR antisecretory efficacy: 10 mM Mg2+ reduced forskolin-induced CFTR-mediated Cl− secretion by ~65% in T84 cells; suppressed cholera toxin and ETEC ST responses by ~50%; luminal 20 mM Mg2+ lowered cholera loop fluid accumulation by ~40%; 10 mM Mg2+ in perfusate converted secretion to net absorption. (Jan 2024) (goncalves2024mg2+supplementationtreats pages 1-2, goncalves2024mg2+supplementationtreats pages 8-10) - EAEC burden and AMR (UK 2016–2023): 1,402 EAEC notifications; fivefold increase in annual diagnoses (93→524); 79% of travel-history cases reported foreign travel within 7 days; AMR in 73.5% isolates, fluoroquinolone resistance 57.8%, β-lactam resistance 57.6%; travel to Indian subcontinent, Egypt, Morocco, Mexico common. (Nov 2025) (poh2025microbiologyandepidemiology pages 10-12) - EPEC transporter impacts: Inhibition of NHE3 and DRA, SGLT1 suppression, SERT inhibition, reduced MCT1/ASBT—mechanistic basis for impaired NaCl absorption, reduced SCFA uptake, and enhanced 5-HT–driven secretion. (Apr 2023) (kaur2023pathophysiologyofenteropathogenic pages 11-12)

Mechanistic Map and Ontology-Linked Summary | Pathogen/Trigger | Principal Toxins / Virulence | Primary Host Targets (HGNC where applicable) | Second Messengers | Key Cellular Processes (GO term names) | Affected Cell Types (CL term names) | Anatomical Sites (UBERON terms) | Notable Chemical Entities (CHEBI names) | Notes / Phenotypes (HP terms & evidence) | |---|---|---|---|---|---|---|---|---| | ETEC (STa / LT) | STa → GC-C activation; LT → ADP‑ribosylation → ↑cAMP; colonization fimbriae | GUCY2C (HGNC:4683); CFTR (HGNC:1884); SLC9A3 / NHE3 (HGNC:11076); SLC5A1 / SGLT1 (HGNC:11036) | cGMP (STa), cAMP (LT) | chloride transport; regulation of cAMP-mediated signaling; inhibition of Na+/H+ exchange; tight junction assembly (disruption) | enterocyte; intestinal goblet cell; submucosal secretomotor neuron | small intestine; jejunum; ileum | cGMP; cAMP; Ca2+ | Secretory watery diarrhea, NHE3 inhibition, dehydration (ye2024baicalinaluminumcomplexon pages 4-9, morris2001viii.pathologicalconsequences pages 5-7) | | EAEC (AggR/AAF, Pic, EAST1) | Aggregative adherence fimbriae (AAFs), AggR-regulated factors; mucin/adhesion enzymes (Pic); EAST1 toxin in some strains | Host mucins/adhesion receptors (CEACAM family implicated in E. coli interactions); enterocyte surface glycoconjugates (no single HGNC) | Local signaling (NF-κB, IL-8), biofilm-associated signals | biofilm formation; actin cytoskeleton organization; inflammatory response | enterocyte; intestinal goblet cell; tuft cell | small intestine; colon | serotonin; bile acid | Prolonged/mucoid diarrhea, persistent colonization; high AMR carriage in EAEC from travellers (poh2025microbiologyandepidemiology pages 10-12) | | EPEC (LEE / T3SS: EspF, Tir, Map, EspG) | Type III secretion effectors: Tir–intimin adhesion, EspF/Map/EspG disrupt junctions, mitochondrial and trafficking targets | CFTR (HGNC:1884) implicated indirectly; SLC9A3 / NHE3 (HGNC:11076) inhibited; SLC26A3 / DRA (HGNC:11059) reduced; SLC5A1 / SGLT1 (HGNC:11036) inhibited; NHERF2 interactions | Perturbation of local signaling (NF-κB), altered Ca2+-dependent cytoskeletal signaling | tight junction assembly (disruption); actin cytoskeleton organization; regulation of cAMP-mediated signaling; epithelial cell apoptosis | enterocyte; intestinal goblet cell; enteroendocrine cell | small intestine; jejunum; ileum | cAMP; cGMP; serotonin; bile acid | Attaching/effacing lesions, microvillus effacement, impaired NaCl absorption (NHE3/DRA/SGLT1), barrier loss → watery diarrhea (kaur2023pathophysiologyofenteropathogenic pages 11-12, kaur2023pathophysiologyofenteropathogenic pages 9-11) | | Campylobacter jejuni | Invasion factors; cytolethal distending toxin (CDT); motility/adhesins → epithelial invasion and IL-8–driven neutrophilic inflammation | Tight junction proteins (claudins), epithelial receptors involved in invasion (no single HGNC), immune receptors on neutrophils | Proinflammatory mediators (IL-8), neutrophil-derived AMP → adenosine/secretagogue signaling | inflammatory response; epithelial cell apoptosis; actin cytoskeleton organization | enterocyte; neutrophil; submucosal secretomotor neuron | ileum; colon | adenosine; serotonin; bile acid | Inflammatory/bloody or inflammatory watery diarrhea; risk of post-infectious IBS (PI‑IBS) and sustained dysbiosis (morris2001viii.pathologicalconsequences pages 5-7, poh2025microbiologyandepidemiology pages 10-12) | | Viral (Rotavirus NSP4; Norovirus) | Rotavirus NSP4 (viral enterotoxin → intracellular Ca2+ mobilization); noroviruses activate enteric secretion and ENS pathways | Enterocyte; enteric neurons; transporters are functionally affected (CFTR may be bypassed early) — CFTR (HGNC:1884) relevance varies | Ca2+ (NSP4); secondary cAMP/cGMP and ENS neurotransmitters (VIP, 5‑HT) | chloride transport; regulation of cAMP-mediated signaling; epithelial cell apoptosis; tight junction assembly (disruption) | enterocyte; enteroendocrine cell; submucosal secretomotor neuron | small intestine; jejunum | Ca2+; cAMP; cGMP; serotonin | Age-dependent secretory diarrhea (NSP4 Ca2+-dependent early phase; ENS-mediated later phase); NSP4 causes CFTR-independent secretion early (morris2001viii.pathologicalconsequences pages 5-7) |

Table: Concise mechanism-to-ontology mapping for major travelers' diarrhea causes, summarizing toxins/virulence, host targets (HGNC), second messengers, GO processes, cell types (CL), anatomical sites (UBERON), key chemicals (CHEBI), and clinical phenotypes with source citations for each row.

Key Molecular Players - Genes/Proteins (HGNC): CFTR (HGNC:1884); GUCY2C/GC-C (HGNC:4683); SLC9A3/NHE3 (HGNC:11076); SLC26A3/DRA (HGNC:11059); SLC5A1/SGLT1 (HGNC:11036); CaSR (HGNC:1514). EPEC effectors: Tir, EspF, EspG, Map, NleA; ETEC toxins: LT (enterotoxin), STa (guanylin-mimetic); EAEC regulators/adhesins: AggR, aggregative adherence fimbriae (AAF). (kaur2023pathophysiologyofenteropathogenic pages 11-12, kaur2023pathophysiologyofenteropathogenic pages 21-25, ye2024baicalinaluminumcomplexon pages 4-9, goncalves2024mg2+supplementationtreats pages 1-2) - Chemical entities (CHEBI): cAMP; cGMP; Ca2+; Mg2+; serotonin (5-HT); bile acid. (morris2001viii.pathologicalconsequences pages 5-7, ye2024baicalinaluminumcomplexon pages 4-9, goncalves2024mg2+supplementationtreats pages 1-2) - Cell types (CL): enterocyte; intestinal goblet cell; enteroendocrine cell; submucosal secretomotor neuron; neutrophil. (morris2001viii.pathologicalconsequences pages 5-7, kaur2023pathophysiologyofenteropathogenic pages 11-12) - Anatomical locations (UBERON): small intestine; jejunum; ileum; colon. (goncalves2024mg2+supplementationtreats pages 1-2, kaur2023pathophysiologyofenteropathogenic pages 11-12)

Biological Processes (GO annotations; disrupted) - Chloride transport; regulation of cAMP-mediated signaling; regulation of cGMP-mediated signaling; positive regulation of CFTR activity; negative regulation of Na+/H+ exchange; tight junction assembly (disruption); actin cytoskeleton organization; inflammatory response; epithelial cell apoptosis; regulation of serotonin uptake. (kaur2023pathophysiologyofenteropathogenic pages 11-12, morris2001viii.pathologicalconsequences pages 5-7, ye2024baicalinaluminumcomplexon pages 4-9, goncalves2024mg2+supplementationtreats pages 1-2)

Cellular Components - Apical plasma membrane (CFTR, NHE3, SGLT1); brush border/microvilli; tight junctions (claudins, ZO-1/ZO-2); basolateral K+ channels; endoplasmic reticulum (NSP4/Ca2+ mobilization); T3SS translocon at epithelial membrane. (kaur2023pathophysiologyofenteropathogenic pages 11-12, morris2001viii.pathologicalconsequences pages 5-7, goncalves2024mg2+supplementationtreats pages 1-2)

Disease Progression Model - Exposure and colonization: Pathogen ingestion → mucosal adherence via fimbriae/adhesins (e.g., ETEC colonization factors; EAEC AAF; EPEC intimin/Tir). (kaur2023pathophysiologyofenteropathogenic pages 11-12, poh2025microbiologyandepidemiology pages 10-12) - Toxin/effectors and signaling: ETEC STa/LT trigger cGMP/cAMP, activating CFTR and inhibiting NHE3; EPEC T3SS effectors disrupt junctions and transporters; viral NSP4 mobilizes Ca2+. (ye2024baicalinaluminumcomplexon pages 4-9, kaur2023pathophysiologyofenteropathogenic pages 11-12, morris2001viii.pathologicalconsequences pages 5-7) - Barrier and transport failure: Reduced DRA/SLC26A3 and SGLT1 impair electroneutral NaCl and glucose-coupled absorption; SERT inhibition enhances 5-HT; microvillus effacement and junctional disassembly increase permeability. (kaur2023pathophysiologyofenteropathogenic pages 11-12) - Amplification: ENS and inflammatory mediators (VIP, 5-HT, PGE2, NO; neutrophil-derived adenosine) sustain secretion. (morris2001viii.pathologicalconsequences pages 5-7) - Clinical manifestation: Acute watery diarrhea (often voluminous), cramping, dehydration; EAEC can be prolonged/persistent. (poh2025microbiologyandepidemiology pages 10-12)

Phenotypic Manifestations (HP terms) - Diarrhea (HP:0002014); Dehydration (HP:0001944); Abdominal cramping (HP:0002027); Intestinal malabsorption (HP:0002571); Increased intestinal fluid secretion (pathophysiologic phenotype). Mechanistic associations supported by transporter dysfunction (NHE3/DRA/SGLT1), CFTR activation, and ENS/inflammatory pathways. (kaur2023pathophysiologyofenteropathogenic pages 11-12, morris2001viii.pathologicalconsequences pages 5-7, ye2024baicalinaluminumcomplexon pages 4-9, goncalves2024mg2+supplementationtreats pages 1-2)

Evidence Items (selected, with URLs and dates) - EPEC pathophysiology (transporters/barrier): Kaur & Dudeja, Newborn, Apr 2023. URL: https://doi.org/10.5005/jp-journals-11002-0056 (kaur2023pathophysiologyofenteropathogenic pages 11-12, kaur2023pathophysiologyofenteropathogenic pages 21-25) - ETEC signaling and epithelial responses: Ye et al., Heliyon, Jun 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e33038 (ye2024baicalinaluminumcomplexon pages 4-9) - Mg2+-CaSR antisecretory therapy: de Souza Goncalves et al., JCI, Jan 2024. URL: https://doi.org/10.1172/jci171249 (goncalves2024mg2+supplementationtreats pages 1-2, goncalves2024mg2+supplementationtreats pages 8-10, goncalves2024mg2+supplementationtreats pages 2-5) - Viral/ENS mechanisms: Morris & Estes, AJP-GI, Aug 2001. URL: https://doi.org/10.1152/ajpgi.2001.281.2.g303 (morris2001viii.pathologicalconsequences pages 5-7) - CEACAM interactions: Sheikh & Fleckenstein, Front. Immunol., Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1120331 (sheikh2023interactionsofpathogenic pages 2-3) - EAEC epidemiology and AMR (travel-associated): Poh et al., J. Med. Microbiol., Nov 2025. URL: https://doi.org/10.1099/jmm.0.002097 (poh2025microbiologyandepidemiology pages 10-12)

Gaps and Open Questions - Campylobacter- and norovirus-specific epithelial signaling in TD requires further recent primary studies to detail transporter-level effects and post-infectious sequelae risk in travelers; however, inflammatory and ENS-mediated mechanisms that amplify secretion are well-supported. (morris2001viii.pathologicalconsequences pages 5-7)

Conclusions TD pathophysiology reflects convergent mechanisms that activate CFTR and disable NaCl/solute absorption, compounded by barrier injury and neuro-immune amplification. The 2023–2024 literature refines EPEC transporter pathobiology and consolidates ETEC cyclic-nucleotide signaling, while a 2024 translational study identifies Mg2+-CaSR activation as a promising, physiology-aligned antisecretory strategy suitable for ORS enhancement. Concurrently, EAEC remains a common, often travel-associated pathogen with substantial AMR burden, underscoring the need for sustained surveillance and judicious antimicrobial use. (kaur2023pathophysiologyofenteropathogenic pages 11-12, kaur2023pathophysiologyofenteropathogenic pages 21-25, ye2024baicalinaluminumcomplexon pages 4-9, poh2025microbiologyandepidemiology pages 10-12, goncalves2024mg2+supplementationtreats pages 1-2, goncalves2024mg2+supplementationtreats pages 8-10)

References

  1. (kaur2023pathophysiologyofenteropathogenic pages 11-12): Prabhdeep Kaur and Pradeep K Dudeja. Pathophysiology of enteropathogenic escherichia coli-induced diarrhea. Newborn (Clarksville, Md.), 2:102-113, Apr 2023. URL: https://doi.org/10.5005/jp-journals-11002-0056, doi:10.5005/jp-journals-11002-0056. This article has 28 citations.

  2. (kaur2023pathophysiologyofenteropathogenic pages 21-25): Prabhdeep Kaur and Pradeep K Dudeja. Pathophysiology of enteropathogenic escherichia coli-induced diarrhea. Newborn (Clarksville, Md.), 2:102-113, Apr 2023. URL: https://doi.org/10.5005/jp-journals-11002-0056, doi:10.5005/jp-journals-11002-0056. This article has 28 citations.

  3. (ye2024baicalinaluminumcomplexon pages 4-9): Chun Ye, Yuqian Chen, Ruixue Yu, Ming Zhao, Ronghua Yin, Yinsheng Qiu, Shulin Fu, Yu Liu, and Zhongyuan Wu. Baicalin-aluminum complex on the regulation of ipec-1 infected with enterotoxigenic escherichia coli. Heliyon, 10:e33038, Jun 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e33038, doi:10.1016/j.heliyon.2024.e33038. This article has 4 citations and is from a peer-reviewed journal.

  4. (poh2025microbiologyandepidemiology pages 10-12): Ching-Ying J. Poh, Ella V. Rodwell, David R. Greig, Satheesh Nair, Marie A. Chattaway, and Claire Jenkins. Microbiology and epidemiology of enteroaggregative escherichia coli isolated from uk residents in england, 2016–2023: what are the risks to public health? Journal of Medical Microbiology, Nov 2025. URL: https://doi.org/10.1099/jmm.0.002097, doi:10.1099/jmm.0.002097. This article has 0 citations and is from a peer-reviewed journal.

  5. (goncalves2024mg2+supplementationtreats pages 1-2): Livia de Souza Goncalves, Tifany Chu, Riya Master, Parth D. Chhetri, Qi Gao, and Onur Cil. Mg2+ supplementation treats secretory diarrhea in mice by activating calcium-sensing receptor in intestinal epithelial cells. Journal of Clinical Investigation, Jan 2024. URL: https://doi.org/10.1172/jci171249, doi:10.1172/jci171249. This article has 9 citations and is from a highest quality peer-reviewed journal.

  6. (goncalves2024mg2+supplementationtreats pages 8-10): Livia de Souza Goncalves, Tifany Chu, Riya Master, Parth D. Chhetri, Qi Gao, and Onur Cil. Mg2+ supplementation treats secretory diarrhea in mice by activating calcium-sensing receptor in intestinal epithelial cells. Journal of Clinical Investigation, Jan 2024. URL: https://doi.org/10.1172/jci171249, doi:10.1172/jci171249. This article has 9 citations and is from a highest quality peer-reviewed journal.

  7. (morris2001viii.pathologicalconsequences pages 5-7): Andrew P. Morris and Mary K. Estes. Viii. pathological consequences of rotavirus infection and its enterotoxin. American Journal of Physiology-Gastrointestinal and Liver Physiology, 281:G303-G310, Aug 2001. URL: https://doi.org/10.1152/ajpgi.2001.281.2.g303, doi:10.1152/ajpgi.2001.281.2.g303. This article has 68 citations.

  8. (sheikh2023interactionsofpathogenic pages 2-3): Alaullah Sheikh and James M. Fleckenstein. Interactions of pathogenic escherichia coli with ceacams. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1120331, doi:10.3389/fimmu.2023.1120331. This article has 12 citations and is from a peer-reviewed journal.

  9. (goncalves2024mg2+supplementationtreats pages 10-11): Livia de Souza Goncalves, Tifany Chu, Riya Master, Parth D. Chhetri, Qi Gao, and Onur Cil. Mg2+ supplementation treats secretory diarrhea in mice by activating calcium-sensing receptor in intestinal epithelial cells. Journal of Clinical Investigation, Jan 2024. URL: https://doi.org/10.1172/jci171249, doi:10.1172/jci171249. This article has 9 citations and is from a highest quality peer-reviewed journal.

  10. (goncalves2024mg2+supplementationtreats pages 2-5): Livia de Souza Goncalves, Tifany Chu, Riya Master, Parth D. Chhetri, Qi Gao, and Onur Cil. Mg2+ supplementation treats secretory diarrhea in mice by activating calcium-sensing receptor in intestinal epithelial cells. Journal of Clinical Investigation, Jan 2024. URL: https://doi.org/10.1172/jci171249, doi:10.1172/jci171249. This article has 9 citations and is from a highest quality peer-reviewed journal.

  11. (kaur2023pathophysiologyofenteropathogenic pages 9-11): Prabhdeep Kaur and Pradeep K Dudeja. Pathophysiology of enteropathogenic escherichia coli-induced diarrhea. Newborn (Clarksville, Md.), 2:102-113, Apr 2023. URL: https://doi.org/10.5005/jp-journals-11002-0056, doi:10.5005/jp-journals-11002-0056. This article has 28 citations.